TY  - JOUR
AU  - Nedeljković, Milica
AU  - Tanić, Nasta
AU  - Prvanović, Mirjana
AU  - Milovanović, Zorka
AU  - Tanić, Nikola
PY  - 2021
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/9173
AB  - Background: ATP-binding cassette (ABC) transporters are responsible for the efflux of a wide variety of anti-cancer agents and have been implicated in the chemoresistance of various solid tumors. Chemoresistance is a major cause of therapeutic failure, especially in the highly aggressive triple-negative breast cancer (TNBC) in which, unlike estrogen receptor-expressing (ER+) BC, both endocrine and targeted treatments are ineffectual. We aimed to investigate the level and frequency of expression of the three most important ABC transporter, ABCG2, ABCC1, and ABCB1, according to breast cancer subtype. Methods: We evaluated ABCG2, ABCC1, and ABCB1 protein expressions in 124 primary breast tumors (78 samples were classified as TNBC, while 46 were classified as ER+) by immunohistochemistry and correlated it to clinicopathological characteristics and outcome. Results: All three transporters had significantly higher expression and were more frequently expressed in TNBC compared to ER+ tumors (p < 0.0001). ABCG2 and ABCC1 had a very high level of expression in TNBC that was significantly greater compared to ABCB1 (p < 0.0001). ABCB1 expression was associated with TNBC metastatic spread (p = 0.03). In contrast, TNBC patients with high ABCG2 expression level had significantly longer disease-free interval (p = 0.03) and overall survival (p = 0.007). Conclusion: ABCG2, ABCC1, and ABCB1 expression in breast cancer is subtype-specific and associated with triple-negative tumors. The expression of ABCB1 may be useful as a marker of metastatic spread. Moreover, unexpectedly, our results showed a beneficial effect of ABCG2 expression on TNBC clinical behavior. These findings could have implications for the implementation of future TNBC treatment strategies.
T2  - Breast Cancer
T1  - Friend or foe: ABCG2, ABCC1 and ABCB1 expression in triple-negative breast cancer
VL  - 28
IS  - 3
SP  - 727
EP  - 736
DO  - 10.1007/s12282-020-01210-z
ER  - 

@article{
author = "Nedeljković, Milica and Tanić, Nasta and Prvanović, Mirjana and Milovanović, Zorka and Tanić, Nikola",
year = "2021",
abstract = "Background: ATP-binding cassette (ABC) transporters are responsible for the efflux of a wide variety of anti-cancer agents and have been implicated in the chemoresistance of various solid tumors. Chemoresistance is a major cause of therapeutic failure, especially in the highly aggressive triple-negative breast cancer (TNBC) in which, unlike estrogen receptor-expressing (ER+) BC, both endocrine and targeted treatments are ineffectual. We aimed to investigate the level and frequency of expression of the three most important ABC transporter, ABCG2, ABCC1, and ABCB1, according to breast cancer subtype. Methods: We evaluated ABCG2, ABCC1, and ABCB1 protein expressions in 124 primary breast tumors (78 samples were classified as TNBC, while 46 were classified as ER+) by immunohistochemistry and correlated it to clinicopathological characteristics and outcome. Results: All three transporters had significantly higher expression and were more frequently expressed in TNBC compared to ER+ tumors (p < 0.0001). ABCG2 and ABCC1 had a very high level of expression in TNBC that was significantly greater compared to ABCB1 (p < 0.0001). ABCB1 expression was associated with TNBC metastatic spread (p = 0.03). In contrast, TNBC patients with high ABCG2 expression level had significantly longer disease-free interval (p = 0.03) and overall survival (p = 0.007). Conclusion: ABCG2, ABCC1, and ABCB1 expression in breast cancer is subtype-specific and associated with triple-negative tumors. The expression of ABCB1 may be useful as a marker of metastatic spread. Moreover, unexpectedly, our results showed a beneficial effect of ABCG2 expression on TNBC clinical behavior. These findings could have implications for the implementation of future TNBC treatment strategies.",
journal = "Breast Cancer",
title = "Friend or foe: ABCG2, ABCC1 and ABCB1 expression in triple-negative breast cancer",
volume = "28",
number = "3",
pages = "727-736",
doi = "10.1007/s12282-020-01210-z"
}

Nedeljković, M., Tanić, N., Prvanović, M., Milovanović, Z.,& Tanić, N.. (2021). Friend or foe: ABCG2, ABCC1 and ABCB1 expression in triple-negative breast cancer. in Breast Cancer, 28(3), 727-736.
https://doi.org/10.1007/s12282-020-01210-z

Nedeljković M, Tanić N, Prvanović M, Milovanović Z, Tanić N. Friend or foe: ABCG2, ABCC1 and ABCB1 expression in triple-negative breast cancer. in Breast Cancer. 2021;28(3):727-736.
doi:10.1007/s12282-020-01210-z .

Nedeljković, Milica, Tanić, Nasta, Prvanović, Mirjana, Milovanović, Zorka, Tanić, Nikola, "Friend or foe: ABCG2, ABCC1 and ABCB1 expression in triple-negative breast cancer" in Breast Cancer, 28, no. 3 (2021):727-736,
https://doi.org/10.1007/s12282-020-01210-z . .

TY  - JOUR
AU  - Prvanović, Mirjana
AU  - Nedeljković, Milica
AU  - Tanić, Nasta
AU  - Tomić, Tijana
AU  - Terzić, Tanja
AU  - Milovanović, Zorka
AU  - Maksimović, Zlatko
AU  - Tanić, Nikola
PY  - 2021
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/10064
AB  - Breast cancer is the most commonly occurring malignancy and the leading cause of cancer-related death in women. Triple-negative breast cancer (TNBC) is the most aggressive subtype and is associated with high recurrence rates, high incidence of distant metastases, and poor overall survival. The aim of this study was to investigate the PI3K/PTEN/Akt/mTOR pathway as one of the most frequently deregulated pathways in cancer. We aimed to explore the impact of PI3K and mTOR oncogenes as well as the PTEN tumor suppressor on TNBC clinical behavior, prognosis, and multidrug resistance (MDR), using immunohistochemistry and copy number analysis by quantitative real-time PCR. Our results revealed that loss of PTEN and high expression of PI3K and mTOR proteins are associated with poor outcome of TNBC patients. PTEN deletions appeared as a major cause of reduced or absent PTEN expression in TNBC. Importantly, homozygous deletions of PTEN (and not hemizygous deletions) are a potential molecular marker of metastasis formation and good predictors of TNBC outcome. In conclusion, we believe that concurrent examination of PTEN/PI3K/mTOR protein expression may be more useful in predicting TNBC clinical course than the analysis of single protein expression. Specifically, our results showed that PTEN-reduced/PI3K-high/mTOR-high expression constitutes a 'high risk' profile of TNBC.
T2  - Life (Basel, Switzerland)
T1  - Role of PTEN, PI3K, and mTOR in Triple-Negative Breast Cancer.
VL  - 11
IS  - 11
SP  - 1247
DO  - 10.3390/life11111247
ER  - 

@article{
author = "Prvanović, Mirjana and Nedeljković, Milica and Tanić, Nasta and Tomić, Tijana and Terzić, Tanja and Milovanović, Zorka and Maksimović, Zlatko and Tanić, Nikola",
year = "2021",
abstract = "Breast cancer is the most commonly occurring malignancy and the leading cause of cancer-related death in women. Triple-negative breast cancer (TNBC) is the most aggressive subtype and is associated with high recurrence rates, high incidence of distant metastases, and poor overall survival. The aim of this study was to investigate the PI3K/PTEN/Akt/mTOR pathway as one of the most frequently deregulated pathways in cancer. We aimed to explore the impact of PI3K and mTOR oncogenes as well as the PTEN tumor suppressor on TNBC clinical behavior, prognosis, and multidrug resistance (MDR), using immunohistochemistry and copy number analysis by quantitative real-time PCR. Our results revealed that loss of PTEN and high expression of PI3K and mTOR proteins are associated with poor outcome of TNBC patients. PTEN deletions appeared as a major cause of reduced or absent PTEN expression in TNBC. Importantly, homozygous deletions of PTEN (and not hemizygous deletions) are a potential molecular marker of metastasis formation and good predictors of TNBC outcome. In conclusion, we believe that concurrent examination of PTEN/PI3K/mTOR protein expression may be more useful in predicting TNBC clinical course than the analysis of single protein expression. Specifically, our results showed that PTEN-reduced/PI3K-high/mTOR-high expression constitutes a 'high risk' profile of TNBC.",
journal = "Life (Basel, Switzerland)",
title = "Role of PTEN, PI3K, and mTOR in Triple-Negative Breast Cancer.",
volume = "11",
number = "11",
pages = "1247",
doi = "10.3390/life11111247"
}

Prvanović, M., Nedeljković, M., Tanić, N., Tomić, T., Terzić, T., Milovanović, Z., Maksimović, Z.,& Tanić, N.. (2021). Role of PTEN, PI3K, and mTOR in Triple-Negative Breast Cancer.. in Life (Basel, Switzerland), 11(11), 1247.
https://doi.org/10.3390/life11111247

Prvanović M, Nedeljković M, Tanić N, Tomić T, Terzić T, Milovanović Z, Maksimović Z, Tanić N. Role of PTEN, PI3K, and mTOR in Triple-Negative Breast Cancer.. in Life (Basel, Switzerland). 2021;11(11):1247.
doi:10.3390/life11111247 .

Prvanović, Mirjana, Nedeljković, Milica, Tanić, Nasta, Tomić, Tijana, Terzić, Tanja, Milovanović, Zorka, Maksimović, Zlatko, Tanić, Nikola, "Role of PTEN, PI3K, and mTOR in Triple-Negative Breast Cancer." in Life (Basel, Switzerland), 11, no. 11 (2021):1247,
https://doi.org/10.3390/life11111247 . .

TY  - JOUR
AU  - Milanović, Srđan
AU  - Potkonjak, Nebojša I.
AU  - Mandušić, Vesna
AU  - Čokeša, Đuro
AU  - Hranisavljević, Jelena
AU  - Kaluđerović, Branka V.
PY  - 2020
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/8975
AB  - Carbonaceous materials as well as its form functionalized with metallic silver have been prepared by hydrothermal carbonization of fructose. Results are presented to show that nanostructured silver was obtained through the functionalization process. The carbonaceous materials were characterized by: nitrogen adsorption/desorption measurement, XRD, SEM/EDS and FTIR. Samples functionalized with silver were analyzed by: XRD and SEM/EDS. The XRD analysis showed that the carbonaceous materials functionalized with silver by hydrothermal carbonization process were successfully performed. Size of silver particles was found to be approximately 32 nm, indicating formation of nanostructure. All samples were tested as an antimicrobial agent for water disinfection. Presence of nanostructured silver in the sample containing 1 mg/mL carbonaceous materials significantly decreased the number of CFU (dCFU = 97.33 %) if compared to the same sample containing the same amount of carbonaceous materials but without of silver (dCFU 65.33 %).
T2  - Science of Sintering
T1  - Antimicrobial effects of carbonaceous material functionalized with silver
VL  - 52
IS  - 1
SP  - 87
EP  - 95
DO  - 10.2298/SOS2001087M
ER  - 

@article{
author = "Milanović, Srđan and Potkonjak, Nebojša I. and Mandušić, Vesna and Čokeša, Đuro and Hranisavljević, Jelena and Kaluđerović, Branka V.",
year = "2020",
abstract = "Carbonaceous materials as well as its form functionalized with metallic silver have been prepared by hydrothermal carbonization of fructose. Results are presented to show that nanostructured silver was obtained through the functionalization process. The carbonaceous materials were characterized by: nitrogen adsorption/desorption measurement, XRD, SEM/EDS and FTIR. Samples functionalized with silver were analyzed by: XRD and SEM/EDS. The XRD analysis showed that the carbonaceous materials functionalized with silver by hydrothermal carbonization process were successfully performed. Size of silver particles was found to be approximately 32 nm, indicating formation of nanostructure. All samples were tested as an antimicrobial agent for water disinfection. Presence of nanostructured silver in the sample containing 1 mg/mL carbonaceous materials significantly decreased the number of CFU (dCFU = 97.33 %) if compared to the same sample containing the same amount of carbonaceous materials but without of silver (dCFU 65.33 %).",
journal = "Science of Sintering",
title = "Antimicrobial effects of carbonaceous material functionalized with silver",
volume = "52",
number = "1",
pages = "87-95",
doi = "10.2298/SOS2001087M"
}

Milanović, S., Potkonjak, N. I., Mandušić, V., Čokeša, Đ., Hranisavljević, J.,& Kaluđerović, B. V.. (2020). Antimicrobial effects of carbonaceous material functionalized with silver. in Science of Sintering, 52(1), 87-95.
https://doi.org/10.2298/SOS2001087M

Milanović S, Potkonjak NI, Mandušić V, Čokeša Đ, Hranisavljević J, Kaluđerović BV. Antimicrobial effects of carbonaceous material functionalized with silver. in Science of Sintering. 2020;52(1):87-95.
doi:10.2298/SOS2001087M .

Milanović, Srđan, Potkonjak, Nebojša I., Mandušić, Vesna, Čokeša, Đuro, Hranisavljević, Jelena, Kaluđerović, Branka V., "Antimicrobial effects of carbonaceous material functionalized with silver" in Science of Sintering, 52, no. 1 (2020):87-95,
https://doi.org/10.2298/SOS2001087M . .

TY  - JOUR
AU  - Todorović, Lidija
AU  - Mandušić, Vesna
AU  - Vučetić-Tadić, Biljana
AU  - Živaljević, Vladan
AU  - Paunović, Ivan
AU  - Stanojević, Boban
PY  - 2020
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/9055
AB  - A growing number of studies suggest a tumor suppressive role and potential prognostic significance of miR- 30a-3p in different types of cancer. However, relatively few studies have focused on this microRNA in neoplastic thyroid lesions, including papillary thyroid cancer (PTC). The aim of our study was to shed more light on the potential involvement and clinical relevance of miR-30a-3p in this type of cancer. We examined the expression levels of this microRNA in 42 pairs of PTCs and matched non-tumor thyroid tissues using quantitative RT-PCR. We analyzed their association with clinical and histopathological parameters. The results revealed that miR-30a-3p was significantly downregulated in the majority of PTC tissues compared to corresponding non-tumor tissues. Moreover, decreased expression of miR-30a-3p was associated with advanced clinical stage, presence of multiple tumor foci and capsular invasion, suggesting a role in aggressive disease. Although the role of this microRNA and its prognostic utility remain to be elucidated, the presented data suggest that downregulated expression of miR-30a-3p indicates poorer prognosis in PTC patients, warranting further investigations.
T2  - Archives of Biological Sciences
T1  - Altered expression of microRNA-30a-3p in papillary thyroid cancer and its association with clinicopathological characteristics
VL  - 72
IS  - 1
SP  - 31
EP  - 36
DO  - 10.2298/ABS191004063T
ER  - 

@article{
author = "Todorović, Lidija and Mandušić, Vesna and Vučetić-Tadić, Biljana and Živaljević, Vladan and Paunović, Ivan and Stanojević, Boban",
year = "2020",
abstract = "A growing number of studies suggest a tumor suppressive role and potential prognostic significance of miR- 30a-3p in different types of cancer. However, relatively few studies have focused on this microRNA in neoplastic thyroid lesions, including papillary thyroid cancer (PTC). The aim of our study was to shed more light on the potential involvement and clinical relevance of miR-30a-3p in this type of cancer. We examined the expression levels of this microRNA in 42 pairs of PTCs and matched non-tumor thyroid tissues using quantitative RT-PCR. We analyzed their association with clinical and histopathological parameters. The results revealed that miR-30a-3p was significantly downregulated in the majority of PTC tissues compared to corresponding non-tumor tissues. Moreover, decreased expression of miR-30a-3p was associated with advanced clinical stage, presence of multiple tumor foci and capsular invasion, suggesting a role in aggressive disease. Although the role of this microRNA and its prognostic utility remain to be elucidated, the presented data suggest that downregulated expression of miR-30a-3p indicates poorer prognosis in PTC patients, warranting further investigations.",
journal = "Archives of Biological Sciences",
title = "Altered expression of microRNA-30a-3p in papillary thyroid cancer and its association with clinicopathological characteristics",
volume = "72",
number = "1",
pages = "31-36",
doi = "10.2298/ABS191004063T"
}

Todorović, L., Mandušić, V., Vučetić-Tadić, B., Živaljević, V., Paunović, I.,& Stanojević, B.. (2020). Altered expression of microRNA-30a-3p in papillary thyroid cancer and its association with clinicopathological characteristics. in Archives of Biological Sciences, 72(1), 31-36.
https://doi.org/10.2298/ABS191004063T

Todorović L, Mandušić V, Vučetić-Tadić B, Živaljević V, Paunović I, Stanojević B. Altered expression of microRNA-30a-3p in papillary thyroid cancer and its association with clinicopathological characteristics. in Archives of Biological Sciences. 2020;72(1):31-36.
doi:10.2298/ABS191004063T .

Todorović, Lidija, Mandušić, Vesna, Vučetić-Tadić, Biljana, Živaljević, Vladan, Paunović, Ivan, Stanojević, Boban, "Altered expression of microRNA-30a-3p in papillary thyroid cancer and its association with clinicopathological characteristics" in Archives of Biological Sciences, 72, no. 1 (2020):31-36,
https://doi.org/10.2298/ABS191004063T . .

TY  - JOUR
AU  - Kožik, Bojana
AU  - Kokanov, Nikola
AU  - Knežević-Ušaj, Slavica
AU  - Nikolić, Ivan
AU  - Davidović, Radoslav S.
AU  - Jovanović-Ćupić, Snežana P.
AU  - Krajnović, Milena M.
PY  - 2018
UR  - http://www.doiserbia.nb.rs/Article.aspx?ID=0354-46641800030K
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/8002
AB  - Methylation of p16 and p14 genes is a common event in colorectal cancers; however, their exact role in the prediction of patients' outcome is unclear. We conducted this retrospective study to evaluate their potential predictive and/or prognostic roles. Methylation-specific PCR was used to examine the methylation status of p16 and p14 in pretherapeutic and preoperative biopsy specimens of 60 patients with locally advanced rectal cancer. The methylation status of the examined genes did not affect the response to preoperative chemoradiotherapy (CRT), recurrence rate and overall survival. However, patients with a simultaneous presence of either p16 or p14 methylation and high vascular endothelial growth factor (VEGF) expression showed a significantly worse response to CRT (p=0.005 and p=0.038, respectively). Moreover, patients with both p16 methylation and high VEGF expression had significantly shorter overall survival (p=0.010), while no such association was found in patients with p14 methylation and high VEGF expression. On the other hand, a subgroup of patients with p16 methylation and low VEGF and high epidermal growth factor receptor (EGFR) expression showed a significantly better response to CRT (p=0.024). The obtained results point to the importance of p16 and p14 methylation analyses in combination with VEGF and EGFR expression, aimed at better predicting treatment response and patient outcome. © 2018 by the Serbian Biological Society.
T2  - Archives of Biological Sciences
T1  - Methylation status of p16 and p14 genes in locally advanced rectal cancer: Potential clinical implication
VL  - 70
IS  - 4
SP  - 681
EP  - 690
DO  - 10.2298/ABS180316030K
ER  - 

@article{
author = "Kožik, Bojana and Kokanov, Nikola and Knežević-Ušaj, Slavica and Nikolić, Ivan and Davidović, Radoslav S. and Jovanović-Ćupić, Snežana P. and Krajnović, Milena M.",
year = "2018",
abstract = "Methylation of p16 and p14 genes is a common event in colorectal cancers; however, their exact role in the prediction of patients' outcome is unclear. We conducted this retrospective study to evaluate their potential predictive and/or prognostic roles. Methylation-specific PCR was used to examine the methylation status of p16 and p14 in pretherapeutic and preoperative biopsy specimens of 60 patients with locally advanced rectal cancer. The methylation status of the examined genes did not affect the response to preoperative chemoradiotherapy (CRT), recurrence rate and overall survival. However, patients with a simultaneous presence of either p16 or p14 methylation and high vascular endothelial growth factor (VEGF) expression showed a significantly worse response to CRT (p=0.005 and p=0.038, respectively). Moreover, patients with both p16 methylation and high VEGF expression had significantly shorter overall survival (p=0.010), while no such association was found in patients with p14 methylation and high VEGF expression. On the other hand, a subgroup of patients with p16 methylation and low VEGF and high epidermal growth factor receptor (EGFR) expression showed a significantly better response to CRT (p=0.024). The obtained results point to the importance of p16 and p14 methylation analyses in combination with VEGF and EGFR expression, aimed at better predicting treatment response and patient outcome. © 2018 by the Serbian Biological Society.",
journal = "Archives of Biological Sciences",
title = "Methylation status of p16 and p14 genes in locally advanced rectal cancer: Potential clinical implication",
volume = "70",
number = "4",
pages = "681-690",
doi = "10.2298/ABS180316030K"
}

Kožik, B., Kokanov, N., Knežević-Ušaj, S., Nikolić, I., Davidović, R. S., Jovanović-Ćupić, S. P.,& Krajnović, M. M.. (2018). Methylation status of p16 and p14 genes in locally advanced rectal cancer: Potential clinical implication. in Archives of Biological Sciences, 70(4), 681-690.
https://doi.org/10.2298/ABS180316030K

Kožik B, Kokanov N, Knežević-Ušaj S, Nikolić I, Davidović RS, Jovanović-Ćupić SP, Krajnović MM. Methylation status of p16 and p14 genes in locally advanced rectal cancer: Potential clinical implication. in Archives of Biological Sciences. 2018;70(4):681-690.
doi:10.2298/ABS180316030K .

Kožik, Bojana, Kokanov, Nikola, Knežević-Ušaj, Slavica, Nikolić, Ivan, Davidović, Radoslav S., Jovanović-Ćupić, Snežana P., Krajnović, Milena M., "Methylation status of p16 and p14 genes in locally advanced rectal cancer: Potential clinical implication" in Archives of Biological Sciences, 70, no. 4 (2018):681-690,
https://doi.org/10.2298/ABS180316030K . .

TY  - JOUR
AU  - Todorović, Lidija
AU  - Stanojević, Boban
AU  - Mandušić, Vesna
AU  - Petrović, Nina
AU  - Živaljević, Vladan R.
AU  - Paunović, Ivan R.
AU  - Diklić, Aleksandar
AU  - Saenko, Vladimir
AU  - Yamashita, Shunichi
PY  - 2018
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/1944
AB  - A growing body of evidence suggests a role of the von Hippel-Lindau (VHL) tumor suppressor gene in the progression of papillary thyroid carcinoma (PTC). Our previous study of VHL in PTCs showed that lower VHL expression was associated with aggressive tumor features, but we found no evidence for VHL downregulation through common genetic or epigenetic modifications. Several studies pointed to a role of microRNA-92a (miR-92a) in the regulation of VHL expression in different cancers. In the present study, we examined the expression levels of VHL mRNA and miR-92a in 42 pairs of PTCs and matched non-tumor thyroid tissues by means of quantitative RT-PCR. We explored the correlation between them and their association with clinicopathological parameters. The results revealed that both VHL and miR-92a were either up-or downregulated in PTCs compared to corresponding non-tumor tissues. On univariate analysis, lower VHL levels were significantly associated with extrathyroid spread (P = 0.022) and capsular invasion (P = 0.032). Multivariate analysis confirmed the association of low VHL with extrathyroid spread (OR 0.246, 95% CI 0.069-0.872, P = 0.038). Higher miR-92a among PTC tissues associated with the presence of nodal metastases (univariate analysis: P = 0.012; multivariate: OR 4.703, 95% CI 1.109-19.938, P = 0.036). A negative correlation between VHL and miR-92a was observed in a subgroup of PTCs having vascular invasion (P = 0.033, r = -0.673). The data here reported demonstrate that the expression of both VHL and miR-92a is deregulated in PTC tissues and that in some PTCs they may have opposite roles. These roles, as well as their diagnostic and/or prognostic utility, remain to be clarified.
T2  - Medical Oncology
T1  - Expression of VHL tumor suppressor mRNA and miR-92a in papillary thyroid carcinoma and their correlation with clinical and pathological parameters
VL  - 35
IS  - 2
DO  - 10.1007/s12032-017-1066-3
ER  - 

@article{
author = "Todorović, Lidija and Stanojević, Boban and Mandušić, Vesna and Petrović, Nina and Živaljević, Vladan R. and Paunović, Ivan R. and Diklić, Aleksandar and Saenko, Vladimir and Yamashita, Shunichi",
year = "2018",
abstract = "A growing body of evidence suggests a role of the von Hippel-Lindau (VHL) tumor suppressor gene in the progression of papillary thyroid carcinoma (PTC). Our previous study of VHL in PTCs showed that lower VHL expression was associated with aggressive tumor features, but we found no evidence for VHL downregulation through common genetic or epigenetic modifications. Several studies pointed to a role of microRNA-92a (miR-92a) in the regulation of VHL expression in different cancers. In the present study, we examined the expression levels of VHL mRNA and miR-92a in 42 pairs of PTCs and matched non-tumor thyroid tissues by means of quantitative RT-PCR. We explored the correlation between them and their association with clinicopathological parameters. The results revealed that both VHL and miR-92a were either up-or downregulated in PTCs compared to corresponding non-tumor tissues. On univariate analysis, lower VHL levels were significantly associated with extrathyroid spread (P = 0.022) and capsular invasion (P = 0.032). Multivariate analysis confirmed the association of low VHL with extrathyroid spread (OR 0.246, 95% CI 0.069-0.872, P = 0.038). Higher miR-92a among PTC tissues associated with the presence of nodal metastases (univariate analysis: P = 0.012; multivariate: OR 4.703, 95% CI 1.109-19.938, P = 0.036). A negative correlation between VHL and miR-92a was observed in a subgroup of PTCs having vascular invasion (P = 0.033, r = -0.673). The data here reported demonstrate that the expression of both VHL and miR-92a is deregulated in PTC tissues and that in some PTCs they may have opposite roles. These roles, as well as their diagnostic and/or prognostic utility, remain to be clarified.",
journal = "Medical Oncology",
title = "Expression of VHL tumor suppressor mRNA and miR-92a in papillary thyroid carcinoma and their correlation with clinical and pathological parameters",
volume = "35",
number = "2",
doi = "10.1007/s12032-017-1066-3"
}

Todorović, L., Stanojević, B., Mandušić, V., Petrović, N., Živaljević, V. R., Paunović, I. R., Diklić, A., Saenko, V.,& Yamashita, S.. (2018). Expression of VHL tumor suppressor mRNA and miR-92a in papillary thyroid carcinoma and their correlation with clinical and pathological parameters. in Medical Oncology, 35(2).
https://doi.org/10.1007/s12032-017-1066-3

Todorović L, Stanojević B, Mandušić V, Petrović N, Živaljević VR, Paunović IR, Diklić A, Saenko V, Yamashita S. Expression of VHL tumor suppressor mRNA and miR-92a in papillary thyroid carcinoma and their correlation with clinical and pathological parameters. in Medical Oncology. 2018;35(2).
doi:10.1007/s12032-017-1066-3 .

Todorović, Lidija, Stanojević, Boban, Mandušić, Vesna, Petrović, Nina, Živaljević, Vladan R., Paunović, Ivan R., Diklić, Aleksandar, Saenko, Vladimir, Yamashita, Shunichi, "Expression of VHL tumor suppressor mRNA and miR-92a in papillary thyroid carcinoma and their correlation with clinical and pathological parameters" in Medical Oncology, 35, no. 2 (2018),
https://doi.org/10.1007/s12032-017-1066-3 . .

TY  - JOUR
AU  - Nedeljković, Milica
AU  - Tanić, Nikola
AU  - Dramićanin, Tatjana
AU  - Milovanović, Zorka M.
AU  - Šušnjar, Snežana
AU  - Milinković, Vedrana
AU  - Vujović, Ivana
AU  - Tanić, Nasta
PY  - 2018
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/7683
AB  - © 2018 Milica Nedeljković et al., published by De Gruyter Open 2018. Background: Triple negative breast cancer (TNBC) is characterized by aggressive clinical course and is unresponsive to anti-HER2 and endocrine therapy. TNBC is difficult to treat and is often lethal. Given the need to find new targets for therapy we explored clinicopathological significance of copy number gain of FGFR1 and c-MYC. Our aim was to determine the impact of FGFR1 and c-MYC copy number gain on clinical course and outcome of TNBC. Methods: FGFR1 and c-MYC gene copy number alterations were evaluated in 78 archive TNBC samples using TaqMan based quantitative real time PCR assays. Results: 50% of samples had increased c-MYC copy number. c-MYC copy number gain was associated with TNBC in contrast to ER positive cancers. Our results showed significant correlation between c-MYC copy number gain and high grade of TNBCs. This suggests that c-MYC copy number could be an useful prognostic marker for TNBC patients. c-MYC copy number gain was associated with high pTNM stage as well as lobular and medullary tumor subtypes. 43% of samples had increased FGFR1 copy number. No correlations between FGFR1 copy number gain and clinicopathological variables were observed. Conclusions: We identified c-MYC copy number gain as a prognostic marker for TNBC. Our results indicate that c- MYC may contribute to TNBC progression. We observed no significant association between c-MYC and/or FGFR1 copy number status and patient survival.
T2  - Journal of Medical Biochemistry
T1  - Importance of Copy Number Alterations of FGFR1 and C-MYC Genes in Triple Negative Breast Cancer
T1  - Značaj promena broja kopija FGFR1 i c-MYC gena u trostruko negativnim karcinomima dojke
VL  - 37
IS  - 2
SP  - 1
EP  - 8
DO  - 10.1515/jomb-2018-0012
ER  - 

@article{
author = "Nedeljković, Milica and Tanić, Nikola and Dramićanin, Tatjana and Milovanović, Zorka M. and Šušnjar, Snežana and Milinković, Vedrana and Vujović, Ivana and Tanić, Nasta",
year = "2018",
abstract = "© 2018 Milica Nedeljković et al., published by De Gruyter Open 2018. Background: Triple negative breast cancer (TNBC) is characterized by aggressive clinical course and is unresponsive to anti-HER2 and endocrine therapy. TNBC is difficult to treat and is often lethal. Given the need to find new targets for therapy we explored clinicopathological significance of copy number gain of FGFR1 and c-MYC. Our aim was to determine the impact of FGFR1 and c-MYC copy number gain on clinical course and outcome of TNBC. Methods: FGFR1 and c-MYC gene copy number alterations were evaluated in 78 archive TNBC samples using TaqMan based quantitative real time PCR assays. Results: 50% of samples had increased c-MYC copy number. c-MYC copy number gain was associated with TNBC in contrast to ER positive cancers. Our results showed significant correlation between c-MYC copy number gain and high grade of TNBCs. This suggests that c-MYC copy number could be an useful prognostic marker for TNBC patients. c-MYC copy number gain was associated with high pTNM stage as well as lobular and medullary tumor subtypes. 43% of samples had increased FGFR1 copy number. No correlations between FGFR1 copy number gain and clinicopathological variables were observed. Conclusions: We identified c-MYC copy number gain as a prognostic marker for TNBC. Our results indicate that c- MYC may contribute to TNBC progression. We observed no significant association between c-MYC and/or FGFR1 copy number status and patient survival.",
journal = "Journal of Medical Biochemistry",
title = "Importance of Copy Number Alterations of FGFR1 and C-MYC Genes in Triple Negative Breast Cancer, Značaj promena broja kopija FGFR1 i c-MYC gena u trostruko negativnim karcinomima dojke",
volume = "37",
number = "2",
pages = "1-8",
doi = "10.1515/jomb-2018-0012"
}

Nedeljković, M., Tanić, N., Dramićanin, T., Milovanović, Z. M., Šušnjar, S., Milinković, V., Vujović, I.,& Tanić, N.. (2018). Importance of Copy Number Alterations of FGFR1 and C-MYC Genes in Triple Negative Breast Cancer. in Journal of Medical Biochemistry, 37(2), 1-8.
https://doi.org/10.1515/jomb-2018-0012

Nedeljković M, Tanić N, Dramićanin T, Milovanović ZM, Šušnjar S, Milinković V, Vujović I, Tanić N. Importance of Copy Number Alterations of FGFR1 and C-MYC Genes in Triple Negative Breast Cancer. in Journal of Medical Biochemistry. 2018;37(2):1-8.
doi:10.1515/jomb-2018-0012 .

Nedeljković, Milica, Tanić, Nikola, Dramićanin, Tatjana, Milovanović, Zorka M., Šušnjar, Snežana, Milinković, Vedrana, Vujović, Ivana, Tanić, Nasta, "Importance of Copy Number Alterations of FGFR1 and C-MYC Genes in Triple Negative Breast Cancer" in Journal of Medical Biochemistry, 37, no. 2 (2018):1-8,
https://doi.org/10.1515/jomb-2018-0012 . .

TY  - JOUR
AU  - Dramićanin, Tatjana
AU  - Lenhardt Acković, Lea
AU  - Zeković, Ivana Lj.
AU  - Dramićanin, Miroslav
PY  - 2018
UR  - https://www.hindawi.com/journals/jspec/2018/8395212/
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/7800
AB  - Honey is a frequent target of adulteration through inappropriate production practices and origin mislabelling. Current methods for the detection of adulterated honey are time and labor consuming, require highly skilled personnel, and lengthy sample preparation. Fluorescence spectroscopy overcomes such drawbacks, as it is fast and noncontact and requires minimal sample preparation. In this paper, the application of fluorescence spectroscopy coupled with statistical tools for the detection of adulterated honey is demonstrated. For this purpose, fluorescence excitation-emission matrices were measured for 99 samples of different types of natural honey and 15 adulterated honey samples (in 3 technical replicas for each sample). Statistical t -test showed that significant differences between fluorescence of natural and adulterated honey samples exist in 5 spectral regions: (1) excitation: 240–265 nm, emission: 370–495 nm; (2) excitation: 280–320 nm, emission: 390–470 nm; (3) excitation: 260–285 nm, emission: 320–370 nm; (4) excitation: 310–360 nm, emission: 370–470 nm; and (5) excitation: 375–435 nm, emission: 440–520 nm, in which majority of fluorescence comes from the aromatic amino acids, phenolic compounds, and fluorescent Maillard reaction products. Principal component analysis confirmed these findings and showed that 90% of variance in fluorescence is accumulated in the first two principal components, which can be used for the discrimination of fake honey samples. The classification of honey from fluorescence data is demonstrated with a linear discriminant analysis (LDA). When subjected to LDA, total fluorescence intensities of selected spectral regions provided classification of honey (natural or adulterated) with 100% accuracy. In addition, it is demonstrated that intensities of honey emissions in each of these spectral regions may serve as criteria for the discrimination between natural and fake honey.
T2  - Journal of Spectroscopy
T1  - Detection of Adulterated Honey by Fluorescence Excitation-Emission Matrices
VL  - 2018
SP  - 1
EP  - 6
DO  - 10.1155/2018/8395212
ER  - 

@article{
author = "Dramićanin, Tatjana and Lenhardt Acković, Lea and Zeković, Ivana Lj. and Dramićanin, Miroslav",
year = "2018",
abstract = "Honey is a frequent target of adulteration through inappropriate production practices and origin mislabelling. Current methods for the detection of adulterated honey are time and labor consuming, require highly skilled personnel, and lengthy sample preparation. Fluorescence spectroscopy overcomes such drawbacks, as it is fast and noncontact and requires minimal sample preparation. In this paper, the application of fluorescence spectroscopy coupled with statistical tools for the detection of adulterated honey is demonstrated. For this purpose, fluorescence excitation-emission matrices were measured for 99 samples of different types of natural honey and 15 adulterated honey samples (in 3 technical replicas for each sample). Statistical t -test showed that significant differences between fluorescence of natural and adulterated honey samples exist in 5 spectral regions: (1) excitation: 240–265 nm, emission: 370–495 nm; (2) excitation: 280–320 nm, emission: 390–470 nm; (3) excitation: 260–285 nm, emission: 320–370 nm; (4) excitation: 310–360 nm, emission: 370–470 nm; and (5) excitation: 375–435 nm, emission: 440–520 nm, in which majority of fluorescence comes from the aromatic amino acids, phenolic compounds, and fluorescent Maillard reaction products. Principal component analysis confirmed these findings and showed that 90% of variance in fluorescence is accumulated in the first two principal components, which can be used for the discrimination of fake honey samples. The classification of honey from fluorescence data is demonstrated with a linear discriminant analysis (LDA). When subjected to LDA, total fluorescence intensities of selected spectral regions provided classification of honey (natural or adulterated) with 100% accuracy. In addition, it is demonstrated that intensities of honey emissions in each of these spectral regions may serve as criteria for the discrimination between natural and fake honey.",
journal = "Journal of Spectroscopy",
title = "Detection of Adulterated Honey by Fluorescence Excitation-Emission Matrices",
volume = "2018",
pages = "1-6",
doi = "10.1155/2018/8395212"
}

Dramićanin, T., Lenhardt Acković, L., Zeković, I. Lj.,& Dramićanin, M.. (2018). Detection of Adulterated Honey by Fluorescence Excitation-Emission Matrices. in Journal of Spectroscopy, 2018, 1-6.
https://doi.org/10.1155/2018/8395212

Dramićanin T, Lenhardt Acković L, Zeković IL, Dramićanin M. Detection of Adulterated Honey by Fluorescence Excitation-Emission Matrices. in Journal of Spectroscopy. 2018;2018:1-6.
doi:10.1155/2018/8395212 .

Dramićanin, Tatjana, Lenhardt Acković, Lea, Zeković, Ivana Lj., Dramićanin, Miroslav, "Detection of Adulterated Honey by Fluorescence Excitation-Emission Matrices" in Journal of Spectroscopy, 2018 (2018):1-6,
https://doi.org/10.1155/2018/8395212 . .

TY  - CONF
AU  - Kožik, Bojana
AU  - Kokanov, Nikola
AU  - Knežević-Ušaj, Slavica
AU  - Nikolić, Ivan
AU  - Davidović, Radoslav
AU  - Jovanović Ćupić, Snežana
AU  - Krajnović, Milena
PY  - 2017
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/12805
AB  - Background: Preoperative chemoradiotherapy (CRT) represents the standard treatment for patients with locally advanced rectal cancer. Since only subset of patients has benefit from this preoperative treatment, development of reliable molecular biomarkers is required. In this retrospective study, we investigated methylation status of p16 and p14 tumor suppressor genes in locally advanced rectal cancer, in order to evaluate their potential predictive and prognostic role. Methods: Methylation-specific PCR was used to examine methylation status of p16 and p14 genes in pretherapeutic and preoperative biopsy specimens of 60 patients with locally advanced rectal cancer. Results: Aberrant methylation of p16 and p14 genes was detected in 43.3% (26/60) and 39.6% (23/58) of cases, respectively. In general, p16 and p14 methylation status did not affect the response to CRT, recurrences rate and overall survival. However, patients with simultaneous presence of either p16 or p14 methylation and high vascular endothelial growth factor (VEGF) expression showed significantly worse response to CRT (p = 0.005 and p = 0.038, respectively). In addition, tendency toward more frequent local recurrences and metastasis was observed in cases with concurrent presence of methylation of either p16 or p14 gene and high VEGF expression (p = 0.075 and p = 0.072, respectively), while patients with both of p16 methylation and high VEGF expression had significantly shorter overall survival (p = 0.010). Conclusion: Obtained results strongly suggest the importance of p16 and p14 methylation analyses in combination with other parameters, particularly VEGF expression, in order to better predict treatment response and patient outcome.
PB  - Belgrade : University of Belgrade, Faculty of Biology
C3  - CoMBoS1 - 1st Congress of Molecular Biologists of Serbia with international participation : Book of abstracts
T1  - Combined analysis of p16 and p14 methylation and VEGF expression status could predict more aggressive phenotype of locally advanced rectal cancers
SP  - 100
EP  - 100
UR  - https://hdl.handle.net/21.15107/rcub_vinar_12805
ER  - 

@conference{
author = "Kožik, Bojana and Kokanov, Nikola and Knežević-Ušaj, Slavica and Nikolić, Ivan and Davidović, Radoslav and Jovanović Ćupić, Snežana and Krajnović, Milena",
year = "2017",
abstract = "Background: Preoperative chemoradiotherapy (CRT) represents the standard treatment for patients with locally advanced rectal cancer. Since only subset of patients has benefit from this preoperative treatment, development of reliable molecular biomarkers is required. In this retrospective study, we investigated methylation status of p16 and p14 tumor suppressor genes in locally advanced rectal cancer, in order to evaluate their potential predictive and prognostic role. Methods: Methylation-specific PCR was used to examine methylation status of p16 and p14 genes in pretherapeutic and preoperative biopsy specimens of 60 patients with locally advanced rectal cancer. Results: Aberrant methylation of p16 and p14 genes was detected in 43.3% (26/60) and 39.6% (23/58) of cases, respectively. In general, p16 and p14 methylation status did not affect the response to CRT, recurrences rate and overall survival. However, patients with simultaneous presence of either p16 or p14 methylation and high vascular endothelial growth factor (VEGF) expression showed significantly worse response to CRT (p = 0.005 and p = 0.038, respectively). In addition, tendency toward more frequent local recurrences and metastasis was observed in cases with concurrent presence of methylation of either p16 or p14 gene and high VEGF expression (p = 0.075 and p = 0.072, respectively), while patients with both of p16 methylation and high VEGF expression had significantly shorter overall survival (p = 0.010). Conclusion: Obtained results strongly suggest the importance of p16 and p14 methylation analyses in combination with other parameters, particularly VEGF expression, in order to better predict treatment response and patient outcome.",
publisher = "Belgrade : University of Belgrade, Faculty of Biology",
journal = "CoMBoS1 - 1st Congress of Molecular Biologists of Serbia with international participation : Book of abstracts",
title = "Combined analysis of p16 and p14 methylation and VEGF expression status could predict more aggressive phenotype of locally advanced rectal cancers",
pages = "100-100",
url = "https://hdl.handle.net/21.15107/rcub_vinar_12805"
}

Kožik, B., Kokanov, N., Knežević-Ušaj, S., Nikolić, I., Davidović, R., Jovanović Ćupić, S.,& Krajnović, M.. (2017). Combined analysis of p16 and p14 methylation and VEGF expression status could predict more aggressive phenotype of locally advanced rectal cancers. in CoMBoS1 - 1st Congress of Molecular Biologists of Serbia with international participation : Book of abstracts
Belgrade : University of Belgrade, Faculty of Biology., 100-100.
https://hdl.handle.net/21.15107/rcub_vinar_12805

Kožik B, Kokanov N, Knežević-Ušaj S, Nikolić I, Davidović R, Jovanović Ćupić S, Krajnović M. Combined analysis of p16 and p14 methylation and VEGF expression status could predict more aggressive phenotype of locally advanced rectal cancers. in CoMBoS1 - 1st Congress of Molecular Biologists of Serbia with international participation : Book of abstracts. 2017;:100-100.
https://hdl.handle.net/21.15107/rcub_vinar_12805 .

Kožik, Bojana, Kokanov, Nikola, Knežević-Ušaj, Slavica, Nikolić, Ivan, Davidović, Radoslav, Jovanović Ćupić, Snežana, Krajnović, Milena, "Combined analysis of p16 and p14 methylation and VEGF expression status could predict more aggressive phenotype of locally advanced rectal cancers" in CoMBoS1 - 1st Congress of Molecular Biologists of Serbia with international participation : Book of abstracts (2017):100-100,
https://hdl.handle.net/21.15107/rcub_vinar_12805 .

TY  - JOUR
AU  - Petrović, Nina
AU  - Sami, Ahmad
AU  - Martinović, Jelena
AU  - Zarić, Marina
AU  - Nakashidze, Irina
AU  - Lukić, Silvana
AU  - Jovanović-Ćupić, Snežana P.
PY  - 2017
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/1805
AB  - Background: Breast carcinomas (BC) belong to a heterogeneous group of malignant diseases. Correct categorization of BC based on molecular biomarkers has a very important role in deciding the proper course of therapy for each patient. It has been already shown that the decrease of TIMP metalloproteinase inhibitor 3 (TIMP-3) together with overexpression of microRNA-21 (miR-21) might be involved in the process of BC invasion. This is the first study that examined relationship among miR-21, TIMP-3 mRNA and TIPM-3 protein levels in BC groups formed according to invasiveness. Methods: In this study, we used 46 breast cancer samples. Estrogen and progesterone receptor (ER, PR) protein levels were evaluated by immunohistochemistry (IHC) method. TIMP-3 mRNA expression was examined by two-step real-time quantitative PCR (qRT-PCR). Western blot analysis was performed for 16 samples. Results: Statistically significant differences in TIMP-3 expression levels between invasive groups were discovered in ER positive (ER+) (p = 0.015), Her-2 negative (p = 0.026) subgroups, and patients without lymph-node metastasis (p = 0.039). Interestingly, significant positive correlation was detected between miR-21 and TIMP-3 mRNA levels (P LT 0.001, p = 0.949) in the group of in situ tumors. TIMP-3 mRNA expression levels highly negatively correlated with levels of miR-21 in PR + invasive BCs (p = 0.007, p = -0.641). TIMP-3 protein levels negatively correlated with miR-21 levels in pure invasive BCs. Conclusion: These data suggest that signaling pathways involved in formation and progression of BCs in groups formed according to invasiveness might be different. Our findings propose that TIMP-3 mRNA expression levels could be significant prognostic parameter, but within specific BC subtypes.
T2  - Pathology Research and Practice
T1  - TIMP-3 mRNA expression levels positively correlates with levels of miR-21 in in situ BC and negatively in PR positive invasive BC
VL  - 213
IS  - 10
SP  - 1264
EP  - 1270
DO  - 10.1016/j.prp.2017.08.012
ER  - 

@article{
author = "Petrović, Nina and Sami, Ahmad and Martinović, Jelena and Zarić, Marina and Nakashidze, Irina and Lukić, Silvana and Jovanović-Ćupić, Snežana P.",
year = "2017",
abstract = "Background: Breast carcinomas (BC) belong to a heterogeneous group of malignant diseases. Correct categorization of BC based on molecular biomarkers has a very important role in deciding the proper course of therapy for each patient. It has been already shown that the decrease of TIMP metalloproteinase inhibitor 3 (TIMP-3) together with overexpression of microRNA-21 (miR-21) might be involved in the process of BC invasion. This is the first study that examined relationship among miR-21, TIMP-3 mRNA and TIPM-3 protein levels in BC groups formed according to invasiveness. Methods: In this study, we used 46 breast cancer samples. Estrogen and progesterone receptor (ER, PR) protein levels were evaluated by immunohistochemistry (IHC) method. TIMP-3 mRNA expression was examined by two-step real-time quantitative PCR (qRT-PCR). Western blot analysis was performed for 16 samples. Results: Statistically significant differences in TIMP-3 expression levels between invasive groups were discovered in ER positive (ER+) (p = 0.015), Her-2 negative (p = 0.026) subgroups, and patients without lymph-node metastasis (p = 0.039). Interestingly, significant positive correlation was detected between miR-21 and TIMP-3 mRNA levels (P LT 0.001, p = 0.949) in the group of in situ tumors. TIMP-3 mRNA expression levels highly negatively correlated with levels of miR-21 in PR + invasive BCs (p = 0.007, p = -0.641). TIMP-3 protein levels negatively correlated with miR-21 levels in pure invasive BCs. Conclusion: These data suggest that signaling pathways involved in formation and progression of BCs in groups formed according to invasiveness might be different. Our findings propose that TIMP-3 mRNA expression levels could be significant prognostic parameter, but within specific BC subtypes.",
journal = "Pathology Research and Practice",
title = "TIMP-3 mRNA expression levels positively correlates with levels of miR-21 in in situ BC and negatively in PR positive invasive BC",
volume = "213",
number = "10",
pages = "1264-1270",
doi = "10.1016/j.prp.2017.08.012"
}

Petrović, N., Sami, A., Martinović, J., Zarić, M., Nakashidze, I., Lukić, S.,& Jovanović-Ćupić, S. P.. (2017). TIMP-3 mRNA expression levels positively correlates with levels of miR-21 in in situ BC and negatively in PR positive invasive BC. in Pathology Research and Practice, 213(10), 1264-1270.
https://doi.org/10.1016/j.prp.2017.08.012

Petrović N, Sami A, Martinović J, Zarić M, Nakashidze I, Lukić S, Jovanović-Ćupić SP. TIMP-3 mRNA expression levels positively correlates with levels of miR-21 in in situ BC and negatively in PR positive invasive BC. in Pathology Research and Practice. 2017;213(10):1264-1270.
doi:10.1016/j.prp.2017.08.012 .

Petrović, Nina, Sami, Ahmad, Martinović, Jelena, Zarić, Marina, Nakashidze, Irina, Lukić, Silvana, Jovanović-Ćupić, Snežana P., "TIMP-3 mRNA expression levels positively correlates with levels of miR-21 in in situ BC and negatively in PR positive invasive BC" in Pathology Research and Practice, 213, no. 10 (2017):1264-1270,
https://doi.org/10.1016/j.prp.2017.08.012 . .

TY  - JOUR
AU  - Petrović, Nina
AU  - Ergun, Sercan
AU  - Isenović, Esma R.
PY  - 2017
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/1736
AB  - MicroRNAs (miRNAs) are post-transcriptional regulators of gene expression, involved in the silencing of messenger RNA (mRNA) translation. The importance of miRNA signatures in disease screening, prognosis, and progression of different tumor types and subtypes is increasing. miRNA expression levels change depending on numerous factors. In this review, we are describing the circumstances under which miRNA levels can change, these are named levels of heterogeneity of miRNAs. miRNAs can have oncogenic, tumor suppressive, or both roles depending on tumor type and target mRNA whose translation they silence. The expression levels of a single miRNA may vary across different cancer types and subtypes, indicating that a miRNA signature may be tissue specific. miRNA levels of expression also vary during disease formation and propagation, indicating the presence of a time profile for their expression. The complexity of the miRNA-mRNA interference network mirrors different genetic and epigenetic changes that influence miRNA and mRNA availability to each other, and hence, their binding ability. The potential role of miRNAs as biomarkers is two-fold; first, for monitoring of the phases of cancer pathogenesis, and second, to characterize the particular type/subtype of cancer. It is important that a particular miRNA should be characterized by examining as many types and subtypes of cancers as are available, as well as being extracted from different types of samples, in order to obtain a complete picture of its behavior and importance in the disease pathology.
T2  - Molecular Diagnosis and Therapy
T1  - Levels of MicroRNA Heterogeneity in Cancer Biology
VL  - 21
IS  - 5
SP  - 511
EP  - 523
DO  - 10.1007/s40291-017-0285-9
ER  - 

@article{
author = "Petrović, Nina and Ergun, Sercan and Isenović, Esma R.",
year = "2017",
abstract = "MicroRNAs (miRNAs) are post-transcriptional regulators of gene expression, involved in the silencing of messenger RNA (mRNA) translation. The importance of miRNA signatures in disease screening, prognosis, and progression of different tumor types and subtypes is increasing. miRNA expression levels change depending on numerous factors. In this review, we are describing the circumstances under which miRNA levels can change, these are named levels of heterogeneity of miRNAs. miRNAs can have oncogenic, tumor suppressive, or both roles depending on tumor type and target mRNA whose translation they silence. The expression levels of a single miRNA may vary across different cancer types and subtypes, indicating that a miRNA signature may be tissue specific. miRNA levels of expression also vary during disease formation and propagation, indicating the presence of a time profile for their expression. The complexity of the miRNA-mRNA interference network mirrors different genetic and epigenetic changes that influence miRNA and mRNA availability to each other, and hence, their binding ability. The potential role of miRNAs as biomarkers is two-fold; first, for monitoring of the phases of cancer pathogenesis, and second, to characterize the particular type/subtype of cancer. It is important that a particular miRNA should be characterized by examining as many types and subtypes of cancers as are available, as well as being extracted from different types of samples, in order to obtain a complete picture of its behavior and importance in the disease pathology.",
journal = "Molecular Diagnosis and Therapy",
title = "Levels of MicroRNA Heterogeneity in Cancer Biology",
volume = "21",
number = "5",
pages = "511-523",
doi = "10.1007/s40291-017-0285-9"
}

Petrović, N., Ergun, S.,& Isenović, E. R.. (2017). Levels of MicroRNA Heterogeneity in Cancer Biology. in Molecular Diagnosis and Therapy, 21(5), 511-523.
https://doi.org/10.1007/s40291-017-0285-9

Petrović N, Ergun S, Isenović ER. Levels of MicroRNA Heterogeneity in Cancer Biology. in Molecular Diagnosis and Therapy. 2017;21(5):511-523.
doi:10.1007/s40291-017-0285-9 .

Petrović, Nina, Ergun, Sercan, Isenović, Esma R., "Levels of MicroRNA Heterogeneity in Cancer Biology" in Molecular Diagnosis and Therapy, 21, no. 5 (2017):511-523,
https://doi.org/10.1007/s40291-017-0285-9 . .

TY  - JOUR
AU  - Petrović, Nina
AU  - Davidović, Radoslav S.
AU  - Bajić, Vladan P.
AU  - Obradović, Milan M.
AU  - Isenović, Esma R.
PY  - 2017
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/1614
AB  - Breast cancer (BC) is a heterogeneous disease in an urgent need for developing novel research, classification, and therapy approaches. Breast cancer 1 (BRCA1) and breast cancer 2 (BRCA2) proteins are well described tumor suppressors with great potential to be the subjects of different therapies. MicroRNAs (miRNAs) are genetic elements that might be used to solve the complex BC puzzle. BRCA1 was described to be the target of up to 100 miRNAs. BRCA1 may directly repress miR-155 activity. In addition, miR-15/107/182-mediated downregulation of BRCA1 interrupt DNA repair and may change the course of BC therapy. miR-146a and miR-146-5p silencing BRCA1 may trigger formation of triple-negative and basal-like sporadic BC cases. miR-182 might effect the therapy outcome. miR-21 targeted therapy might be useful for the treatment of BRCA2 mutation carriers. miR-342 overexpression and the absence of functional BRCA1 gene might cause synthetic lethality, which might be used as a base for future therapies. The present review discusses the latest data from studies that focus on the complex network of miRNAs and BRCA1/2 related BCs, which might be important for improving the therapy within the patients with triple-negative BC (TNBC) and basal-like BC, and for understanding the formation of TNBC.
T2  - Cancer Biomarkers
T1  - MicroRNA in breast cancer: The association with BRCA1/2
VL  - 19
IS  - 2
SP  - 119
EP  - 128
DO  - 10.3233/CBM-160319
ER  - 

@article{
author = "Petrović, Nina and Davidović, Radoslav S. and Bajić, Vladan P. and Obradović, Milan M. and Isenović, Esma R.",
year = "2017",
abstract = "Breast cancer (BC) is a heterogeneous disease in an urgent need for developing novel research, classification, and therapy approaches. Breast cancer 1 (BRCA1) and breast cancer 2 (BRCA2) proteins are well described tumor suppressors with great potential to be the subjects of different therapies. MicroRNAs (miRNAs) are genetic elements that might be used to solve the complex BC puzzle. BRCA1 was described to be the target of up to 100 miRNAs. BRCA1 may directly repress miR-155 activity. In addition, miR-15/107/182-mediated downregulation of BRCA1 interrupt DNA repair and may change the course of BC therapy. miR-146a and miR-146-5p silencing BRCA1 may trigger formation of triple-negative and basal-like sporadic BC cases. miR-182 might effect the therapy outcome. miR-21 targeted therapy might be useful for the treatment of BRCA2 mutation carriers. miR-342 overexpression and the absence of functional BRCA1 gene might cause synthetic lethality, which might be used as a base for future therapies. The present review discusses the latest data from studies that focus on the complex network of miRNAs and BRCA1/2 related BCs, which might be important for improving the therapy within the patients with triple-negative BC (TNBC) and basal-like BC, and for understanding the formation of TNBC.",
journal = "Cancer Biomarkers",
title = "MicroRNA in breast cancer: The association with BRCA1/2",
volume = "19",
number = "2",
pages = "119-128",
doi = "10.3233/CBM-160319"
}

Petrović, N., Davidović, R. S., Bajić, V. P., Obradović, M. M.,& Isenović, E. R.. (2017). MicroRNA in breast cancer: The association with BRCA1/2. in Cancer Biomarkers, 19(2), 119-128.
https://doi.org/10.3233/CBM-160319

Petrović N, Davidović RS, Bajić VP, Obradović MM, Isenović ER. MicroRNA in breast cancer: The association with BRCA1/2. in Cancer Biomarkers. 2017;19(2):119-128.
doi:10.3233/CBM-160319 .

Petrović, Nina, Davidović, Radoslav S., Bajić, Vladan P., Obradović, Milan M., Isenović, Esma R., "MicroRNA in breast cancer: The association with BRCA1/2" in Cancer Biomarkers, 19, no. 2 (2017):119-128,
https://doi.org/10.3233/CBM-160319 . .

TY  - JOUR
AU  - Piovesan, Damiano
AU  - Tabaro, Francesco
AU  - Micetic, Ivan
AU  - Necci, Marco
AU  - Quaglia, Federica
AU  - Oldfield, Christopher J.
AU  - Aspromonte, Maria Cristina
AU  - Davey, Norman E.
AU  - Davidović, Radoslav S.
AU  - Dosztanyi, Zsuzsanna
AU  - Elofsson, Arne
AU  - Gasparini, Alessandra
AU  - Hatos, Andras
AU  - Kajava, Andrey V.
AU  - Kalmar, Lajos
AU  - Leonardi, Emanuela
AU  - Lazar, Tamas
AU  - Macedo-Ribeiro, Sandra
AU  - Macossay-Castillo, Mauricio
AU  - Meszaros, Attila
AU  - Minervini, Giovanni
AU  - Murvai, Nikoletta
AU  - Pujols, Jordi
AU  - Roche, Daniel B.
AU  - Salladini, Edoardo
AU  - Schad, Eva
AU  - Schramm, Antoine
AU  - Szabo, Beata
AU  - Tantos, Agnes
AU  - Tonello, Fiorella
AU  - Tsirigos, Konstantinos D.
AU  - Veljković, Nevena V.
AU  - Ventura, Salvador
AU  - Vranken, Wim
AU  - Warholm, Per
AU  - Uversky, Vladimir N.
AU  - Dunker, A. Keith
AU  - Longhi, Sonia
AU  - Tompa, Peter
AU  - Tosatto, Silvio C. E.
PY  - 2017
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/1464
AB  - The Database of Protein Disorder (DisProt, URL: www.disprot.org) has been significantly updated and upgraded since its last major renewal in 2007. The current release holds information on more than 800 entries of IDPs/IDRs, i.e. intrinsically disordered proteins or regions that exist and function without a well-defined three-dimensional structure. We have re-curated previous entries to purge DisProt from conflicting cases, and also upgraded the functional classification scheme to reflect continuous advance in the field in the past 10 years or so. We define IDPs as proteins that are disordered along their entire sequence, i.e. entirely lack structural elements, and IDRs as regions that are at least five consecutive residues without well-defined structure. We base our assessment of disorder strictly on experimental evidence, such as X-ray crystallography and nuclear magnetic resonance ( primary techniques) and a broad range of other experimental approaches (secondary techniques). Confident and ambiguous annotations are highlighted separately. DisProt 7.0 presents classified knowledge regarding the experimental characterization and functional annotations of IDPs/IDRs, and is intended to provide an invaluable resource for the research community for a better understanding structural disorder and for developing better computational tools for studying disordered proteins.
T2  - Nucleic Acids Research
T1  - DisProt 7.0: a major update of the database of disordered proteins
VL  - 45
IS  - D1
SP  - D219
EP  - D227
DO  - 10.1093/nar/gkw1056
ER  - 

@article{
author = "Piovesan, Damiano and Tabaro, Francesco and Micetic, Ivan and Necci, Marco and Quaglia, Federica and Oldfield, Christopher J. and Aspromonte, Maria Cristina and Davey, Norman E. and Davidović, Radoslav S. and Dosztanyi, Zsuzsanna and Elofsson, Arne and Gasparini, Alessandra and Hatos, Andras and Kajava, Andrey V. and Kalmar, Lajos and Leonardi, Emanuela and Lazar, Tamas and Macedo-Ribeiro, Sandra and Macossay-Castillo, Mauricio and Meszaros, Attila and Minervini, Giovanni and Murvai, Nikoletta and Pujols, Jordi and Roche, Daniel B. and Salladini, Edoardo and Schad, Eva and Schramm, Antoine and Szabo, Beata and Tantos, Agnes and Tonello, Fiorella and Tsirigos, Konstantinos D. and Veljković, Nevena V. and Ventura, Salvador and Vranken, Wim and Warholm, Per and Uversky, Vladimir N. and Dunker, A. Keith and Longhi, Sonia and Tompa, Peter and Tosatto, Silvio C. E.",
year = "2017",
abstract = "The Database of Protein Disorder (DisProt, URL: www.disprot.org) has been significantly updated and upgraded since its last major renewal in 2007. The current release holds information on more than 800 entries of IDPs/IDRs, i.e. intrinsically disordered proteins or regions that exist and function without a well-defined three-dimensional structure. We have re-curated previous entries to purge DisProt from conflicting cases, and also upgraded the functional classification scheme to reflect continuous advance in the field in the past 10 years or so. We define IDPs as proteins that are disordered along their entire sequence, i.e. entirely lack structural elements, and IDRs as regions that are at least five consecutive residues without well-defined structure. We base our assessment of disorder strictly on experimental evidence, such as X-ray crystallography and nuclear magnetic resonance ( primary techniques) and a broad range of other experimental approaches (secondary techniques). Confident and ambiguous annotations are highlighted separately. DisProt 7.0 presents classified knowledge regarding the experimental characterization and functional annotations of IDPs/IDRs, and is intended to provide an invaluable resource for the research community for a better understanding structural disorder and for developing better computational tools for studying disordered proteins.",
journal = "Nucleic Acids Research",
title = "DisProt 7.0: a major update of the database of disordered proteins",
volume = "45",
number = "D1",
pages = "D219-D227",
doi = "10.1093/nar/gkw1056"
}

Piovesan, D., Tabaro, F., Micetic, I., Necci, M., Quaglia, F., Oldfield, C. J., Aspromonte, M. C., Davey, N. E., Davidović, R. S., Dosztanyi, Z., Elofsson, A., Gasparini, A., Hatos, A., Kajava, A. V., Kalmar, L., Leonardi, E., Lazar, T., Macedo-Ribeiro, S., Macossay-Castillo, M., Meszaros, A., Minervini, G., Murvai, N., Pujols, J., Roche, D. B., Salladini, E., Schad, E., Schramm, A., Szabo, B., Tantos, A., Tonello, F., Tsirigos, K. D., Veljković, N. V., Ventura, S., Vranken, W., Warholm, P., Uversky, V. N., Dunker, A. K., Longhi, S., Tompa, P.,& Tosatto, S. C. E.. (2017). DisProt 7.0: a major update of the database of disordered proteins. in Nucleic Acids Research, 45(D1), D219-D227.
https://doi.org/10.1093/nar/gkw1056

Piovesan D, Tabaro F, Micetic I, Necci M, Quaglia F, Oldfield CJ, Aspromonte MC, Davey NE, Davidović RS, Dosztanyi Z, Elofsson A, Gasparini A, Hatos A, Kajava AV, Kalmar L, Leonardi E, Lazar T, Macedo-Ribeiro S, Macossay-Castillo M, Meszaros A, Minervini G, Murvai N, Pujols J, Roche DB, Salladini E, Schad E, Schramm A, Szabo B, Tantos A, Tonello F, Tsirigos KD, Veljković NV, Ventura S, Vranken W, Warholm P, Uversky VN, Dunker AK, Longhi S, Tompa P, Tosatto SCE. DisProt 7.0: a major update of the database of disordered proteins. in Nucleic Acids Research. 2017;45(D1):D219-D227.
doi:10.1093/nar/gkw1056 .

Piovesan, Damiano, Tabaro, Francesco, Micetic, Ivan, Necci, Marco, Quaglia, Federica, Oldfield, Christopher J., Aspromonte, Maria Cristina, Davey, Norman E., Davidović, Radoslav S., Dosztanyi, Zsuzsanna, Elofsson, Arne, Gasparini, Alessandra, Hatos, Andras, Kajava, Andrey V., Kalmar, Lajos, Leonardi, Emanuela, Lazar, Tamas, Macedo-Ribeiro, Sandra, Macossay-Castillo, Mauricio, Meszaros, Attila, Minervini, Giovanni, Murvai, Nikoletta, Pujols, Jordi, Roche, Daniel B., Salladini, Edoardo, Schad, Eva, Schramm, Antoine, Szabo, Beata, Tantos, Agnes, Tonello, Fiorella, Tsirigos, Konstantinos D., Veljković, Nevena V., Ventura, Salvador, Vranken, Wim, Warholm, Per, Uversky, Vladimir N., Dunker, A. Keith, Longhi, Sonia, Tompa, Peter, Tosatto, Silvio C. E., "DisProt 7.0: a major update of the database of disordered proteins" in Nucleic Acids Research, 45, no. D1 (2017):D219-D227,
https://doi.org/10.1093/nar/gkw1056 . .

TY  - JOUR
AU  - Petrović, Nina
AU  - Kolaković, Ana
AU  - Stanković, Aleksandra
AU  - Lukić, Silvana
AU  - Sami, Ahmad
AU  - Živković, Maja
AU  - Mandušić, Vesna
PY  - 2016
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/1023
AB  - BACKGROUND: Breast carcinoma is heterogeneous disease. Understanding the process of invasion and metastasis and the selection of the therapy for patients with breast carcinomas still remains difficult. MicroRNAs are powerful gene expression regulators. Because of inconsistent findings, we have analyzed potential difference in miR-155 levels in three breast cancer groups. OBJECTIVES: Our goals were to examine miR-155 expression levels in normal tissue, non-invasive and invasive breast carcinomas, and their association with standard clinical and pathological parameters and oncomiR-21, and to investigate the ability of miR-155 to separate invasive breast carcinomas with non-invasive component from pure invasive. METHODS: In the group of 40 breast tissue samples, relative expression levels of miR-155 were examined with stem-loop quantitative real-time PCR using TaqMan technology. RESULTS: The significant difference among four examined groups of the breast tissue was detected (p = 0.001). In the group of pure invasive tumors, patients with positive nodal status had significantly higher miR-155 levels (p = 0.046). CONCLUSION: Our results suggest that miR-155 might be involved in breast cancer pathogenesis and in tumor spreading to the lymph nodes, and that it might be used as biomarker for additional stratification of patients with invasive breast carcinomas with non-invasive component.
T2  - Cancer Biomarkers
T1  - miR-155 expression level changes might be associated with initial phases of breast cancer pathogenesis and lymph-node metastasis
VL  - 16
IS  - 3
SP  - 385
EP  - 394
DO  - 10.3233/CBM-160577
ER  - 

@article{
author = "Petrović, Nina and Kolaković, Ana and Stanković, Aleksandra and Lukić, Silvana and Sami, Ahmad and Živković, Maja and Mandušić, Vesna",
year = "2016",
abstract = "BACKGROUND: Breast carcinoma is heterogeneous disease. Understanding the process of invasion and metastasis and the selection of the therapy for patients with breast carcinomas still remains difficult. MicroRNAs are powerful gene expression regulators. Because of inconsistent findings, we have analyzed potential difference in miR-155 levels in three breast cancer groups. OBJECTIVES: Our goals were to examine miR-155 expression levels in normal tissue, non-invasive and invasive breast carcinomas, and their association with standard clinical and pathological parameters and oncomiR-21, and to investigate the ability of miR-155 to separate invasive breast carcinomas with non-invasive component from pure invasive. METHODS: In the group of 40 breast tissue samples, relative expression levels of miR-155 were examined with stem-loop quantitative real-time PCR using TaqMan technology. RESULTS: The significant difference among four examined groups of the breast tissue was detected (p = 0.001). In the group of pure invasive tumors, patients with positive nodal status had significantly higher miR-155 levels (p = 0.046). CONCLUSION: Our results suggest that miR-155 might be involved in breast cancer pathogenesis and in tumor spreading to the lymph nodes, and that it might be used as biomarker for additional stratification of patients with invasive breast carcinomas with non-invasive component.",
journal = "Cancer Biomarkers",
title = "miR-155 expression level changes might be associated with initial phases of breast cancer pathogenesis and lymph-node metastasis",
volume = "16",
number = "3",
pages = "385-394",
doi = "10.3233/CBM-160577"
}

Petrović, N., Kolaković, A., Stanković, A., Lukić, S., Sami, A., Živković, M.,& Mandušić, V.. (2016). miR-155 expression level changes might be associated with initial phases of breast cancer pathogenesis and lymph-node metastasis. in Cancer Biomarkers, 16(3), 385-394.
https://doi.org/10.3233/CBM-160577

Petrović N, Kolaković A, Stanković A, Lukić S, Sami A, Živković M, Mandušić V. miR-155 expression level changes might be associated with initial phases of breast cancer pathogenesis and lymph-node metastasis. in Cancer Biomarkers. 2016;16(3):385-394.
doi:10.3233/CBM-160577 .

Petrović, Nina, Kolaković, Ana, Stanković, Aleksandra, Lukić, Silvana, Sami, Ahmad, Živković, Maja, Mandušić, Vesna, "miR-155 expression level changes might be associated with initial phases of breast cancer pathogenesis and lymph-node metastasis" in Cancer Biomarkers, 16, no. 3 (2016):385-394,
https://doi.org/10.3233/CBM-160577 . .

TY  - JOUR
AU  - Petrović, Nina
PY  - 2016
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/985
AB  - Breast cancer (BC) is a heterogeneous disease that develops into a large number of varied phenotypes. One of the features used in its classification and therapy selection is invasiveness. MicroRNA-21 (miR-21) is considered to be an important element of BC invasiveness, and miR-21 levels are frequently increased in different tumor types compared with normal tissue, including the breast. Experimental and literature research has highlighted that miR-21 was always significantly elevated in every study that included invasive breast carcinomas compared with healthy breast tissue. The main goal of this research was to specify the predominant role of miR-21 in the different phases of BC pathogenesis, i.e. whether it was involved in the early (initiation), later (promotion), or late (propagation, progression) phases. Our second goal was to explain the roles of miR-21 targets in BC by an in silico approach and literature review, and to associate the importance of miR-21 with particular phases of BC pathogenesis through the action of its target genes. Analysis has shown that changes in miR-21 levels might be important for the later and/or late phases of breast cancerogenesis rather than for the initial early phases. Targets of miR-21 (TIMP3, PDCD4, PTEN, TPM1 and RECK) are also primarily involved in BC promotion and progression, especially invasion, angiogenesis and metastasis. miR-21 expression levels could perhaps be used in conjunction with the standard diagnostic parameters as an indicator of BC presence, and to indicate a phenotype likely to show early invasion/metastasis detection and poor prognosis.
PB  - Springer
T2  - Molecular Diagnosis and Therapy
T1  - miR-21 Might be Involved in Breast Cancer Promotion and Invasion Rather than in Initial Events of Breast Cancer Development
VL  - 20
IS  - 2
SP  - 97
EP  - 110
DO  - 10.1007/s40291-016-0186-3
ER  - 

@article{
author = "Petrović, Nina",
year = "2016",
abstract = "Breast cancer (BC) is a heterogeneous disease that develops into a large number of varied phenotypes. One of the features used in its classification and therapy selection is invasiveness. MicroRNA-21 (miR-21) is considered to be an important element of BC invasiveness, and miR-21 levels are frequently increased in different tumor types compared with normal tissue, including the breast. Experimental and literature research has highlighted that miR-21 was always significantly elevated in every study that included invasive breast carcinomas compared with healthy breast tissue. The main goal of this research was to specify the predominant role of miR-21 in the different phases of BC pathogenesis, i.e. whether it was involved in the early (initiation), later (promotion), or late (propagation, progression) phases. Our second goal was to explain the roles of miR-21 targets in BC by an in silico approach and literature review, and to associate the importance of miR-21 with particular phases of BC pathogenesis through the action of its target genes. Analysis has shown that changes in miR-21 levels might be important for the later and/or late phases of breast cancerogenesis rather than for the initial early phases. Targets of miR-21 (TIMP3, PDCD4, PTEN, TPM1 and RECK) are also primarily involved in BC promotion and progression, especially invasion, angiogenesis and metastasis. miR-21 expression levels could perhaps be used in conjunction with the standard diagnostic parameters as an indicator of BC presence, and to indicate a phenotype likely to show early invasion/metastasis detection and poor prognosis.",
publisher = "Springer",
journal = "Molecular Diagnosis and Therapy",
title = "miR-21 Might be Involved in Breast Cancer Promotion and Invasion Rather than in Initial Events of Breast Cancer Development",
volume = "20",
number = "2",
pages = "97-110",
doi = "10.1007/s40291-016-0186-3"
}

Petrović, N.. (2016). miR-21 Might be Involved in Breast Cancer Promotion and Invasion Rather than in Initial Events of Breast Cancer Development. in Molecular Diagnosis and Therapy
Springer., 20(2), 97-110.
https://doi.org/10.1007/s40291-016-0186-3

Petrović N. miR-21 Might be Involved in Breast Cancer Promotion and Invasion Rather than in Initial Events of Breast Cancer Development. in Molecular Diagnosis and Therapy. 2016;20(2):97-110.
doi:10.1007/s40291-016-0186-3 .

Petrović, Nina, "miR-21 Might be Involved in Breast Cancer Promotion and Invasion Rather than in Initial Events of Breast Cancer Development" in Molecular Diagnosis and Therapy, 20, no. 2 (2016):97-110,
https://doi.org/10.1007/s40291-016-0186-3 . .

TY  - JOUR
AU  - Ivanović, Vesna
AU  - Dedović-Tanić, Nasta
AU  - Milovanović, Zorka M.
AU  - Lukić, Silvana
AU  - Nikolić, Srđan
AU  - Baltić, Vladimir
AU  - Stojiljković, Bratislav
AU  - Demajo, Miroslav
AU  - Mandušić, Vesna
AU  - Dimitrijević, Bogomir B.
PY  - 2016
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/1327
AB  - We present herein a case report style article on a rare advanced triple-negative breast cancer (TNBC) patient with 6-month disease-free interval, and 10-month overall survival. Our results demonstrate that the poor clinical outcome of this patient was associated with pronounced, more than fivefold higher, overexpression of both cFOS and TGF-beta 1 proteins in its metastatic nodal tissue extracts, when compared with the values of the two non-TNBC controls (with zero disease-free interval and overall survival). This original observation suggests, for the first time, that both the cFOS and TGF-beta 1 may be considered as a pair of biomarkers for an early assessment of poor prognosis for TNBC patients. The possible clinical implication of this observation is discussed.
T2  - Personalized Medicine
T1  - Case with triple-negative breast cancer shows overexpression of both cFOS and TGF-beta 1 in node-positive tissue
VL  - 13
IS  - 6
SP  - 523
EP  - 530
DO  - 10.2217/pme-2016-0032
ER  - 

@article{
author = "Ivanović, Vesna and Dedović-Tanić, Nasta and Milovanović, Zorka M. and Lukić, Silvana and Nikolić, Srđan and Baltić, Vladimir and Stojiljković, Bratislav and Demajo, Miroslav and Mandušić, Vesna and Dimitrijević, Bogomir B.",
year = "2016",
abstract = "We present herein a case report style article on a rare advanced triple-negative breast cancer (TNBC) patient with 6-month disease-free interval, and 10-month overall survival. Our results demonstrate that the poor clinical outcome of this patient was associated with pronounced, more than fivefold higher, overexpression of both cFOS and TGF-beta 1 proteins in its metastatic nodal tissue extracts, when compared with the values of the two non-TNBC controls (with zero disease-free interval and overall survival). This original observation suggests, for the first time, that both the cFOS and TGF-beta 1 may be considered as a pair of biomarkers for an early assessment of poor prognosis for TNBC patients. The possible clinical implication of this observation is discussed.",
journal = "Personalized Medicine",
title = "Case with triple-negative breast cancer shows overexpression of both cFOS and TGF-beta 1 in node-positive tissue",
volume = "13",
number = "6",
pages = "523-530",
doi = "10.2217/pme-2016-0032"
}

Ivanović, V., Dedović-Tanić, N., Milovanović, Z. M., Lukić, S., Nikolić, S., Baltić, V., Stojiljković, B., Demajo, M., Mandušić, V.,& Dimitrijević, B. B.. (2016). Case with triple-negative breast cancer shows overexpression of both cFOS and TGF-beta 1 in node-positive tissue. in Personalized Medicine, 13(6), 523-530.
https://doi.org/10.2217/pme-2016-0032

Ivanović V, Dedović-Tanić N, Milovanović ZM, Lukić S, Nikolić S, Baltić V, Stojiljković B, Demajo M, Mandušić V, Dimitrijević BB. Case with triple-negative breast cancer shows overexpression of both cFOS and TGF-beta 1 in node-positive tissue. in Personalized Medicine. 2016;13(6):523-530.
doi:10.2217/pme-2016-0032 .

Ivanović, Vesna, Dedović-Tanić, Nasta, Milovanović, Zorka M., Lukić, Silvana, Nikolić, Srđan, Baltić, Vladimir, Stojiljković, Bratislav, Demajo, Miroslav, Mandušić, Vesna, Dimitrijević, Bogomir B., "Case with triple-negative breast cancer shows overexpression of both cFOS and TGF-beta 1 in node-positive tissue" in Personalized Medicine, 13, no. 6 (2016):523-530,
https://doi.org/10.2217/pme-2016-0032 . .

TY  - JOUR
AU  - Krajnović, Milena M.
AU  - Marković, Bojana
AU  - Knežević-Ušaj, Slavica
AU  - Nikolic, Ivan
AU  - Stanojevic, Maja
AU  - Nikolić, Valentina
AU  - Siljic, Marina
AU  - Jovanović-Ćupić, Snežana P.
AU  - Dimitrijević, Bogomir B.
PY  - 2016
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/1164
AB  - In this study, we investigated the mutation status of KRAS gene in pretherapeutic and preoperative biopsies in 63 specimens of locally advanced rectal cancers in order to evaluate its potential predictive and/or prognostic role. Regions of interest of KRAS exon 2 were amplified and visualized on 2% agarose gel. Obtained PCR products were subjected to direct sequencing. KRAS mutations were detected in 35% of patients, 91% of which were located in codon 12 and 9% in codon 13. In general, KRAS mutation status did not affect the response to neoadjuvant chemoradiotherapy (CRT). However, patients harboring mutated KRAS gene, simultaneously with high vascular endothelial growth factor (VEGF) expression, exhibited a worse response to CRT (p = 0.030), a more frequent appearance of local recurrences and distant metastasis (p = 0.003), and shorter overall survival (p = 0.001) compared to all others. On the contrary, patients with GGT GT GCT KRAS mutation exhibited a significantly better response to CRT than those with any other type of KRAS mutation (p = 0.017). Moreover, the presence of GGT GT GCT mutation was associated with low VEGF and Ki67 expression (p = 0.012 in both cases), parameters related to less aggressiveness of the disease. Our results suggest that KRAS mutation status could have some predictive and prognostic importance in rectal cancer when analyzed together with other parameters, such as VEGF and Ki67 expression. In addition, it seems that not only the presence but the type of KRAS mutation is important for examining its impact on CRT response. (C) 2016 Elsevier GmbH. All rights reserved.
T2  - Pathology Research and Practice
T1  - Locally advanced rectal cancers with simultaneous occurrence of KRAS mutation and high VEGF expression show invasive characteristics
VL  - 212
IS  - 7
SP  - 598
EP  - 603
DO  - 10.1016/j.prp.2016.02.018
ER  - 

@article{
author = "Krajnović, Milena M. and Marković, Bojana and Knežević-Ušaj, Slavica and Nikolic, Ivan and Stanojevic, Maja and Nikolić, Valentina and Siljic, Marina and Jovanović-Ćupić, Snežana P. and Dimitrijević, Bogomir B.",
year = "2016",
abstract = "In this study, we investigated the mutation status of KRAS gene in pretherapeutic and preoperative biopsies in 63 specimens of locally advanced rectal cancers in order to evaluate its potential predictive and/or prognostic role. Regions of interest of KRAS exon 2 were amplified and visualized on 2% agarose gel. Obtained PCR products were subjected to direct sequencing. KRAS mutations were detected in 35% of patients, 91% of which were located in codon 12 and 9% in codon 13. In general, KRAS mutation status did not affect the response to neoadjuvant chemoradiotherapy (CRT). However, patients harboring mutated KRAS gene, simultaneously with high vascular endothelial growth factor (VEGF) expression, exhibited a worse response to CRT (p = 0.030), a more frequent appearance of local recurrences and distant metastasis (p = 0.003), and shorter overall survival (p = 0.001) compared to all others. On the contrary, patients with GGT GT GCT KRAS mutation exhibited a significantly better response to CRT than those with any other type of KRAS mutation (p = 0.017). Moreover, the presence of GGT GT GCT mutation was associated with low VEGF and Ki67 expression (p = 0.012 in both cases), parameters related to less aggressiveness of the disease. Our results suggest that KRAS mutation status could have some predictive and prognostic importance in rectal cancer when analyzed together with other parameters, such as VEGF and Ki67 expression. In addition, it seems that not only the presence but the type of KRAS mutation is important for examining its impact on CRT response. (C) 2016 Elsevier GmbH. All rights reserved.",
journal = "Pathology Research and Practice",
title = "Locally advanced rectal cancers with simultaneous occurrence of KRAS mutation and high VEGF expression show invasive characteristics",
volume = "212",
number = "7",
pages = "598-603",
doi = "10.1016/j.prp.2016.02.018"
}

Krajnović, M. M., Marković, B., Knežević-Ušaj, S., Nikolic, I., Stanojevic, M., Nikolić, V., Siljic, M., Jovanović-Ćupić, S. P.,& Dimitrijević, B. B.. (2016). Locally advanced rectal cancers with simultaneous occurrence of KRAS mutation and high VEGF expression show invasive characteristics. in Pathology Research and Practice, 212(7), 598-603.
https://doi.org/10.1016/j.prp.2016.02.018

Krajnović MM, Marković B, Knežević-Ušaj S, Nikolic I, Stanojevic M, Nikolić V, Siljic M, Jovanović-Ćupić SP, Dimitrijević BB. Locally advanced rectal cancers with simultaneous occurrence of KRAS mutation and high VEGF expression show invasive characteristics. in Pathology Research and Practice. 2016;212(7):598-603.
doi:10.1016/j.prp.2016.02.018 .

Krajnović, Milena M., Marković, Bojana, Knežević-Ušaj, Slavica, Nikolic, Ivan, Stanojevic, Maja, Nikolić, Valentina, Siljic, Marina, Jovanović-Ćupić, Snežana P., Dimitrijević, Bogomir B., "Locally advanced rectal cancers with simultaneous occurrence of KRAS mutation and high VEGF expression show invasive characteristics" in Pathology Research and Practice, 212, no. 7 (2016):598-603,
https://doi.org/10.1016/j.prp.2016.02.018 . .

TY  - JOUR
AU  - Jovanović-Ćupić, Snežana P.
AU  - Glišić, Sanja
AU  - Stanojevic, Maja
AU  - Nozic, Darko
AU  - Petrović, Nina
AU  - Mandušić, Vesna
AU  - Krajnović, Milena M.
PY  - 2016
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/1032
AB  - The goal of this study was to identify host and viral factors affecting the response to pegylated interferon/ribavirin (PEG-IFN/RBV) treatment in patients with chronic hepatitis C genotype 1b. Baseline characteristics of the patients and sequences within the p7 region were analyzed in pre-treatment serum samples from 53 individuals with chronic hepatitis C genotype 1b and related to the outcome of therapy. We found a significant correlation between age and response to therapy (p LT 0.001). Furthermore, the pre-treatment viral load was closely associated with the stage of liver fibrosis (p LT 0.001). The presence of fewer than 4 mutations and age above 40 were significantly associated with non-response (NR) (p LT 0.001). Our findings may be useful for estimating the likelihood of achieving a sustained virologic response (SVR) in patients who are chronically infected with hepatitis C virus genotype 1b.
PB  - Springer
T2  - Archives of Virology
T1  - The influence of host factors and sequence variability of the p7 region on the response to pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b in patients from Serbia
VL  - 161
IS  - 5
SP  - 1189
EP  - 1198
DO  - 10.1007/s00705-016-2777-z
ER  - 

@article{
author = "Jovanović-Ćupić, Snežana P. and Glišić, Sanja and Stanojevic, Maja and Nozic, Darko and Petrović, Nina and Mandušić, Vesna and Krajnović, Milena M.",
year = "2016",
abstract = "The goal of this study was to identify host and viral factors affecting the response to pegylated interferon/ribavirin (PEG-IFN/RBV) treatment in patients with chronic hepatitis C genotype 1b. Baseline characteristics of the patients and sequences within the p7 region were analyzed in pre-treatment serum samples from 53 individuals with chronic hepatitis C genotype 1b and related to the outcome of therapy. We found a significant correlation between age and response to therapy (p LT 0.001). Furthermore, the pre-treatment viral load was closely associated with the stage of liver fibrosis (p LT 0.001). The presence of fewer than 4 mutations and age above 40 were significantly associated with non-response (NR) (p LT 0.001). Our findings may be useful for estimating the likelihood of achieving a sustained virologic response (SVR) in patients who are chronically infected with hepatitis C virus genotype 1b.",
publisher = "Springer",
journal = "Archives of Virology",
title = "The influence of host factors and sequence variability of the p7 region on the response to pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b in patients from Serbia",
volume = "161",
number = "5",
pages = "1189-1198",
doi = "10.1007/s00705-016-2777-z"
}

Jovanović-Ćupić, S. P., Glišić, S., Stanojevic, M., Nozic, D., Petrović, N., Mandušić, V.,& Krajnović, M. M.. (2016). The influence of host factors and sequence variability of the p7 region on the response to pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b in patients from Serbia. in Archives of Virology
Springer., 161(5), 1189-1198.
https://doi.org/10.1007/s00705-016-2777-z

Jovanović-Ćupić SP, Glišić S, Stanojevic M, Nozic D, Petrović N, Mandušić V, Krajnović MM. The influence of host factors and sequence variability of the p7 region on the response to pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b in patients from Serbia. in Archives of Virology. 2016;161(5):1189-1198.
doi:10.1007/s00705-016-2777-z .

Jovanović-Ćupić, Snežana P., Glišić, Sanja, Stanojevic, Maja, Nozic, Darko, Petrović, Nina, Mandušić, Vesna, Krajnović, Milena M., "The influence of host factors and sequence variability of the p7 region on the response to pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b in patients from Serbia" in Archives of Virology, 161, no. 5 (2016):1189-1198,
https://doi.org/10.1007/s00705-016-2777-z . .

TY  - JOUR
AU  - Petrović, Nina
AU  - Davidović, Radoslav S.
AU  - Jovanović-Ćupić, Snežana P.
AU  - Krajnović, Milena M.
AU  - Lukić, Silvana
AU  - Petrović, Milan
AU  - Roganović, Jelena
PY  - 2016
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/1308
AB  - Breast cancer (BC) is a heterogeneous group of diseases that still represents a major cause of death in the female population. MicroRNAs (miRNAs, miRs), such as miR-221 and miR-222, have been shown to be involved in BC pathology by acting via its target genes such as tissue inhibitor of metalloproteinase 3 (TIMP3). The main goals of this study were to find differences in miR-221/222 levels of expression in BC groups based on invasiveness, and to investigate the association with estrogen receptor (ER), TIMP3 messenger RNA (mRNA) levels, and clinicopathological characteristics of patients and tumors. In this study, we measured levels of miR-221/222 in 63 breast tissue samples by quantitative reverse transcription-polymerase chain reaction (qRT-PCR) using TaqMan(A (R)) technology and immunohistochemistry. miR-221/222 levels varied significantly across groups based on invasiveness (P LT 0.001). In in situ tumors, miR-221 and miR-222 were negatively associated with ER (P = 0.001, r = -0.714, and P = 0.013, r = -0.585, respectively). In invasive breast carcinomas associated with non-invasive tumors, miR-222 was inversely associated with ER (P = 0.039, r = -0.620). Pure invasive BCs showed a positive correlation of miR-221 and miR-222 with TIMP3 mRNA levels (P = 0.008, r = 0.508, and P = 0.010, r = 0.497, respectively). An increase in miR-221/222 might be an important event for in situ carcinoma formation, and miR-221/222 may be important molecules that highlight potential differences between invasive breast carcinomas associated with non-invasive and pure invasive BCs.
T2  - Molecular Diagnosis and Therapy
T1  - Changes in miR-221/222 Levels in Invasive and In Situ Carcinomas of the Breast: Differences in Association with Estrogen Receptor and TIMP3 Expression Levels
VL  - 20
IS  - 6
SP  - 603
EP  - 615
DO  - 10.1007/s40291-016-0230-3
ER  - 

@article{
author = "Petrović, Nina and Davidović, Radoslav S. and Jovanović-Ćupić, Snežana P. and Krajnović, Milena M. and Lukić, Silvana and Petrović, Milan and Roganović, Jelena",
year = "2016",
abstract = "Breast cancer (BC) is a heterogeneous group of diseases that still represents a major cause of death in the female population. MicroRNAs (miRNAs, miRs), such as miR-221 and miR-222, have been shown to be involved in BC pathology by acting via its target genes such as tissue inhibitor of metalloproteinase 3 (TIMP3). The main goals of this study were to find differences in miR-221/222 levels of expression in BC groups based on invasiveness, and to investigate the association with estrogen receptor (ER), TIMP3 messenger RNA (mRNA) levels, and clinicopathological characteristics of patients and tumors. In this study, we measured levels of miR-221/222 in 63 breast tissue samples by quantitative reverse transcription-polymerase chain reaction (qRT-PCR) using TaqMan(A (R)) technology and immunohistochemistry. miR-221/222 levels varied significantly across groups based on invasiveness (P LT 0.001). In in situ tumors, miR-221 and miR-222 were negatively associated with ER (P = 0.001, r = -0.714, and P = 0.013, r = -0.585, respectively). In invasive breast carcinomas associated with non-invasive tumors, miR-222 was inversely associated with ER (P = 0.039, r = -0.620). Pure invasive BCs showed a positive correlation of miR-221 and miR-222 with TIMP3 mRNA levels (P = 0.008, r = 0.508, and P = 0.010, r = 0.497, respectively). An increase in miR-221/222 might be an important event for in situ carcinoma formation, and miR-221/222 may be important molecules that highlight potential differences between invasive breast carcinomas associated with non-invasive and pure invasive BCs.",
journal = "Molecular Diagnosis and Therapy",
title = "Changes in miR-221/222 Levels in Invasive and In Situ Carcinomas of the Breast: Differences in Association with Estrogen Receptor and TIMP3 Expression Levels",
volume = "20",
number = "6",
pages = "603-615",
doi = "10.1007/s40291-016-0230-3"
}

Petrović, N., Davidović, R. S., Jovanović-Ćupić, S. P., Krajnović, M. M., Lukić, S., Petrović, M.,& Roganović, J.. (2016). Changes in miR-221/222 Levels in Invasive and In Situ Carcinomas of the Breast: Differences in Association with Estrogen Receptor and TIMP3 Expression Levels. in Molecular Diagnosis and Therapy, 20(6), 603-615.
https://doi.org/10.1007/s40291-016-0230-3

Petrović N, Davidović RS, Jovanović-Ćupić SP, Krajnović MM, Lukić S, Petrović M, Roganović J. Changes in miR-221/222 Levels in Invasive and In Situ Carcinomas of the Breast: Differences in Association with Estrogen Receptor and TIMP3 Expression Levels. in Molecular Diagnosis and Therapy. 2016;20(6):603-615.
doi:10.1007/s40291-016-0230-3 .

Petrović, Nina, Davidović, Radoslav S., Jovanović-Ćupić, Snežana P., Krajnović, Milena M., Lukić, Silvana, Petrović, Milan, Roganović, Jelena, "Changes in miR-221/222 Levels in Invasive and In Situ Carcinomas of the Breast: Differences in Association with Estrogen Receptor and TIMP3 Expression Levels" in Molecular Diagnosis and Therapy, 20, no. 6 (2016):603-615,
https://doi.org/10.1007/s40291-016-0230-3 . .

TY  - JOUR
AU  - Sopta, Jelena
AU  - Lujić, Nenad
AU  - Kovačević, Relja
AU  - Davidović, Radoslav S.
PY  - 2016
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/1429
AB  - Aim of the study is to determine the possible roles of p53, cyclin D1, B-catenin and Ki-67 in the increase in risk of fractures in patients with giant cell tumor of bone. The study included a total of 164 patients with giant cell tumor of bone (GCTB), 21 (12.8%) with and 143 (87.2%) without fracture. The samples were analyzed immunohistochemically for expression of Ki-67, p53, cyclin D1 and beta-catenin. According to the immunohistochemical expression of p53 and Ki-67 in mononuclear stromal cells, as well as of cyclin D1 in multinuclear giant cells, there was no significant association with immunopositivity and risk of fractures. However, our research revealed that patients with cytoplasmic expression of beta-catenin in stromal cells had three times more frequent occurrence of pathological fractures, which was highly statistically significant (chi(2) = 7.065; p = 0.008). Moreover, a highly statistically significant correlation between the nuclear expression of beta-catenin in giant cells and the incidence of pathological fractures was also found (chi(2) = 8.824; p = 0.003). The study showed that beta-catenin expression highly correlates with the incidence of pathological fractures in patients with GCTB. Taking into account that beta-catenin is closely linked to activation of the Wnt signaling pathway in GCTB pathogenesis, one could postulate that activation of the Wnt pathway is one of the contributing factors to locally destructive behavior of this tumor, as well as to the incidence of pathological fractures.
T2  - Polish Journal of Pathology
T1  - Significance of Beta-Catenin Expression for the Incidence of Pathological Fractures in Giant Cell Tumors of Bone
VL  - 67
IS  - 4
SP  - 345
EP  - 350
DO  - 10.5114/PJP.2016.65866
ER  - 

@article{
author = "Sopta, Jelena and Lujić, Nenad and Kovačević, Relja and Davidović, Radoslav S.",
year = "2016",
abstract = "Aim of the study is to determine the possible roles of p53, cyclin D1, B-catenin and Ki-67 in the increase in risk of fractures in patients with giant cell tumor of bone. The study included a total of 164 patients with giant cell tumor of bone (GCTB), 21 (12.8%) with and 143 (87.2%) without fracture. The samples were analyzed immunohistochemically for expression of Ki-67, p53, cyclin D1 and beta-catenin. According to the immunohistochemical expression of p53 and Ki-67 in mononuclear stromal cells, as well as of cyclin D1 in multinuclear giant cells, there was no significant association with immunopositivity and risk of fractures. However, our research revealed that patients with cytoplasmic expression of beta-catenin in stromal cells had three times more frequent occurrence of pathological fractures, which was highly statistically significant (chi(2) = 7.065; p = 0.008). Moreover, a highly statistically significant correlation between the nuclear expression of beta-catenin in giant cells and the incidence of pathological fractures was also found (chi(2) = 8.824; p = 0.003). The study showed that beta-catenin expression highly correlates with the incidence of pathological fractures in patients with GCTB. Taking into account that beta-catenin is closely linked to activation of the Wnt signaling pathway in GCTB pathogenesis, one could postulate that activation of the Wnt pathway is one of the contributing factors to locally destructive behavior of this tumor, as well as to the incidence of pathological fractures.",
journal = "Polish Journal of Pathology",
title = "Significance of Beta-Catenin Expression for the Incidence of Pathological Fractures in Giant Cell Tumors of Bone",
volume = "67",
number = "4",
pages = "345-350",
doi = "10.5114/PJP.2016.65866"
}

Sopta, J., Lujić, N., Kovačević, R.,& Davidović, R. S.. (2016). Significance of Beta-Catenin Expression for the Incidence of Pathological Fractures in Giant Cell Tumors of Bone. in Polish Journal of Pathology, 67(4), 345-350.
https://doi.org/10.5114/PJP.2016.65866

Sopta J, Lujić N, Kovačević R, Davidović RS. Significance of Beta-Catenin Expression for the Incidence of Pathological Fractures in Giant Cell Tumors of Bone. in Polish Journal of Pathology. 2016;67(4):345-350.
doi:10.5114/PJP.2016.65866 .

Sopta, Jelena, Lujić, Nenad, Kovačević, Relja, Davidović, Radoslav S., "Significance of Beta-Catenin Expression for the Incidence of Pathological Fractures in Giant Cell Tumors of Bone" in Polish Journal of Pathology, 67, no. 4 (2016):345-350,
https://doi.org/10.5114/PJP.2016.65866 . .

TY  - JOUR
AU  - Lujić, Nenad
AU  - Sopta, Jelena
AU  - Kovačević, Relja
AU  - Stevanović, Vladan
AU  - Davidović, Radoslav S.
PY  - 2016
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/1298
AB  - To determine various clinical, radiographic, and pathological parameters which may indicate an increased risk of Giant cell tumour of bone (GCTB) recurrence after surgical therapy. The study included a total of 164 GCTB samples; 118 (72 %) primary tumours, and 46 (28 %) recurrences; which were analyzed on immunohistochemistry for expression of Ki67, p53, cyclin D1, and beta-catenin. Among 13 analyzed clinical, radiological, and histological variables, which presented possible predictive factors for the incidence of GCTB relapse, univariate logistic regression (ULR) extract three highly statistically significant parameters: 1) lesion localization, 2) nuclear p53 expression in mononuclear cells, and 3) nuclear cyclin D1 expression in giant multinuclear cells. The multivariate logistic regression (MLR), revealing that p53 expression in mononuclear cells was the most significant predictive factor (HR = 6,181 p LT 0,001), the positivity of which indicated six times higher probability for recurrence in GCTB. The expression of cyclin D1 in giant cells, containing less than 15 nuclei, was also statistically significant (HR = 8,398, p = 0,038) for predicting the recurrence, and demonstrated eight times more frequent recurrence in positive tumours. This study confirmed independent predicting factors for GCTB reccurence: p53 expression in mononuclear tumour cells and cyclin D1 expression in giant multinuclear cells. Results are new addition to generally known parameters, such as: localization of lesion, number of surgical interventions, clear destruction of cortex with the presence of extracompartmental lesion, and histological criteria for malignancy and can help in further research and treatment of GCTB.
T2  - International Orthopaedics
T1  - Recurrence of giant cell tumour of bone: role of p53, cyclin D1, beta-catenin and Ki67
VL  - 40
IS  - 11
SP  - 2393
EP  - 2399
DO  - 10.1007/s00264-016-3292-2
ER  - 

@article{
author = "Lujić, Nenad and Sopta, Jelena and Kovačević, Relja and Stevanović, Vladan and Davidović, Radoslav S.",
year = "2016",
abstract = "To determine various clinical, radiographic, and pathological parameters which may indicate an increased risk of Giant cell tumour of bone (GCTB) recurrence after surgical therapy. The study included a total of 164 GCTB samples; 118 (72 %) primary tumours, and 46 (28 %) recurrences; which were analyzed on immunohistochemistry for expression of Ki67, p53, cyclin D1, and beta-catenin. Among 13 analyzed clinical, radiological, and histological variables, which presented possible predictive factors for the incidence of GCTB relapse, univariate logistic regression (ULR) extract three highly statistically significant parameters: 1) lesion localization, 2) nuclear p53 expression in mononuclear cells, and 3) nuclear cyclin D1 expression in giant multinuclear cells. The multivariate logistic regression (MLR), revealing that p53 expression in mononuclear cells was the most significant predictive factor (HR = 6,181 p LT 0,001), the positivity of which indicated six times higher probability for recurrence in GCTB. The expression of cyclin D1 in giant cells, containing less than 15 nuclei, was also statistically significant (HR = 8,398, p = 0,038) for predicting the recurrence, and demonstrated eight times more frequent recurrence in positive tumours. This study confirmed independent predicting factors for GCTB reccurence: p53 expression in mononuclear tumour cells and cyclin D1 expression in giant multinuclear cells. Results are new addition to generally known parameters, such as: localization of lesion, number of surgical interventions, clear destruction of cortex with the presence of extracompartmental lesion, and histological criteria for malignancy and can help in further research and treatment of GCTB.",
journal = "International Orthopaedics",
title = "Recurrence of giant cell tumour of bone: role of p53, cyclin D1, beta-catenin and Ki67",
volume = "40",
number = "11",
pages = "2393-2399",
doi = "10.1007/s00264-016-3292-2"
}

Lujić, N., Sopta, J., Kovačević, R., Stevanović, V.,& Davidović, R. S.. (2016). Recurrence of giant cell tumour of bone: role of p53, cyclin D1, beta-catenin and Ki67. in International Orthopaedics, 40(11), 2393-2399.
https://doi.org/10.1007/s00264-016-3292-2

Lujić N, Sopta J, Kovačević R, Stevanović V, Davidović RS. Recurrence of giant cell tumour of bone: role of p53, cyclin D1, beta-catenin and Ki67. in International Orthopaedics. 2016;40(11):2393-2399.
doi:10.1007/s00264-016-3292-2 .

Lujić, Nenad, Sopta, Jelena, Kovačević, Relja, Stevanović, Vladan, Davidović, Radoslav S., "Recurrence of giant cell tumour of bone: role of p53, cyclin D1, beta-catenin and Ki67" in International Orthopaedics, 40, no. 11 (2016):2393-2399,
https://doi.org/10.1007/s00264-016-3292-2 . .

TY  - JOUR
AU  - Bajić, Vladan P.
AU  - Mandušić, Vesna
AU  - Stefanova, Elka
AU  - Božović, Ana M.
AU  - Davidović, Radoslav S.
AU  - Živković, Lada
AU  - Čabarkapa, Andrea
AU  - Spremo-Potparević, Biljana
PY  - 2015
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/314
AB  - X-chromosome instability has been a long established feature in Alzheimers disease ( AD). Premature centromere division and aneuploidy of the X-chromosome has been found in peripheral blood lymphocytes and neuronal tissue in female AD patients. Interestingly, only one chromosome of the X pair has been affected. These results raised a question, Is the X-chromosome inactivation pattern altered in peripheral blood lymphocytes ofwomen affected by AD? To address this question, we analyzed the methylation status of androgen receptor promoter which may show us any deviation from the 50 : 50% X inactivation status in peripheral blood lymphocytes ofwomen with AD. Our results showed skewed inactivation patterns ( GT 90%). These findings suggest that an epigenetic alteration on the inactivation centers of the X-chromosome (or skewing) relates not only to aging, by might be a novel property that could account for the higher incidence of AD in women.
T2  - Journal of Alzheimers Disease
T1  - Skewed X-Chromosome Inactivation in Women Affected by Alzheimers Disease
VL  - 43
IS  - 4
SP  - 1251
EP  - 1259
DO  - 10.3233/JAD-141674
ER  - 

@article{
author = "Bajić, Vladan P. and Mandušić, Vesna and Stefanova, Elka and Božović, Ana M. and Davidović, Radoslav S. and Živković, Lada and Čabarkapa, Andrea and Spremo-Potparević, Biljana",
year = "2015",
abstract = "X-chromosome instability has been a long established feature in Alzheimers disease ( AD). Premature centromere division and aneuploidy of the X-chromosome has been found in peripheral blood lymphocytes and neuronal tissue in female AD patients. Interestingly, only one chromosome of the X pair has been affected. These results raised a question, Is the X-chromosome inactivation pattern altered in peripheral blood lymphocytes ofwomen affected by AD? To address this question, we analyzed the methylation status of androgen receptor promoter which may show us any deviation from the 50 : 50% X inactivation status in peripheral blood lymphocytes ofwomen with AD. Our results showed skewed inactivation patterns ( GT 90%). These findings suggest that an epigenetic alteration on the inactivation centers of the X-chromosome (or skewing) relates not only to aging, by might be a novel property that could account for the higher incidence of AD in women.",
journal = "Journal of Alzheimers Disease",
title = "Skewed X-Chromosome Inactivation in Women Affected by Alzheimers Disease",
volume = "43",
number = "4",
pages = "1251-1259",
doi = "10.3233/JAD-141674"
}

Bajić, V. P., Mandušić, V., Stefanova, E., Božović, A. M., Davidović, R. S., Živković, L., Čabarkapa, A.,& Spremo-Potparević, B.. (2015). Skewed X-Chromosome Inactivation in Women Affected by Alzheimers Disease. in Journal of Alzheimers Disease, 43(4), 1251-1259.
https://doi.org/10.3233/JAD-141674

Bajić VP, Mandušić V, Stefanova E, Božović AM, Davidović RS, Živković L, Čabarkapa A, Spremo-Potparević B. Skewed X-Chromosome Inactivation in Women Affected by Alzheimers Disease. in Journal of Alzheimers Disease. 2015;43(4):1251-1259.
doi:10.3233/JAD-141674 .

Bajić, Vladan P., Mandušić, Vesna, Stefanova, Elka, Božović, Ana M., Davidović, Radoslav S., Živković, Lada, Čabarkapa, Andrea, Spremo-Potparević, Biljana, "Skewed X-Chromosome Inactivation in Women Affected by Alzheimers Disease" in Journal of Alzheimers Disease, 43, no. 4 (2015):1251-1259,
https://doi.org/10.3233/JAD-141674 . .

TY  - JOUR
AU  - Petrović, Nina
AU  - Jovanović-Ćupić, Snežana P.
AU  - Brajušković, Goran
AU  - Lukić, Silvana
AU  - Roganović, Jelena
AU  - Krajnović, Milena M.
AU  - Mandušić, Vesna
PY  - 2015
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/862
AB  - Invasive ductal carcinomas with a non-invasive component (IDC-DCIS) are classified as a group of invasive breast carcinomas, together with pure invasive ductal carcinomas of the breast (IDC). MicroRNA-21 (miR-21) has been characterized as a factor of breast cancer invasiveness, however the difference in miR-21 expression levels between IDC-DCIS and pure IDC tumors and the correlations with standard diagnostic and prognostic parameters inside the IDC-DCIS group are unknown. Our aim was to determine if miR-21 had the ability to distinguish these two invasive breast cancer groups. Levels of miR-21 expression were measured by a stem-loop quantitative Real-Time PCR (RT-qPCR) method. Expression levels of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (Her-2) and proliferative index Ki-67 were evaluated by immunohistochemistry. IDC-DCIS tumors had significantly lower levels of miR-21 expression in grade 2 (P=0.003, Mann-Whitney U test), ER positive (P=0.025, Mann-Whitney U test) and PR positive tumors (P=0.024, Mann-Whitney U test) than pure IDCs. miR-21 levels showed a different pattern of expression in IDC-DCIS compared to IDC tumors, which is based on the difference in miR-21 expression between Her-2 negative and Her-2 positive IDC-DCIS tumors (P=0.030, Mann-Whitney U test) and high negative correlation of miR-21 levels with PR levels (rho=-0.886, P=0.006, Spearman correlation). According to our results, IDC-DCIS breast carcinomas act in a different manner in pure IDC tumors with regard to the relations between miR-21 expression levels and the standard diagnostic and prognostic parameters, such as Her-2 status, ER and PR status and protein levels.
T2  - Archives of Biological Sciences
T1  - Micro Rna-21 Expression Levels in Invasive Breast Carcinoma with a Non-Invasive Component
VL  - 67
IS  - 4
SP  - 1285
EP  - 1295
DO  - 10.2298/ABS150327105P
ER  - 

@article{
author = "Petrović, Nina and Jovanović-Ćupić, Snežana P. and Brajušković, Goran and Lukić, Silvana and Roganović, Jelena and Krajnović, Milena M. and Mandušić, Vesna",
year = "2015",
abstract = "Invasive ductal carcinomas with a non-invasive component (IDC-DCIS) are classified as a group of invasive breast carcinomas, together with pure invasive ductal carcinomas of the breast (IDC). MicroRNA-21 (miR-21) has been characterized as a factor of breast cancer invasiveness, however the difference in miR-21 expression levels between IDC-DCIS and pure IDC tumors and the correlations with standard diagnostic and prognostic parameters inside the IDC-DCIS group are unknown. Our aim was to determine if miR-21 had the ability to distinguish these two invasive breast cancer groups. Levels of miR-21 expression were measured by a stem-loop quantitative Real-Time PCR (RT-qPCR) method. Expression levels of estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (Her-2) and proliferative index Ki-67 were evaluated by immunohistochemistry. IDC-DCIS tumors had significantly lower levels of miR-21 expression in grade 2 (P=0.003, Mann-Whitney U test), ER positive (P=0.025, Mann-Whitney U test) and PR positive tumors (P=0.024, Mann-Whitney U test) than pure IDCs. miR-21 levels showed a different pattern of expression in IDC-DCIS compared to IDC tumors, which is based on the difference in miR-21 expression between Her-2 negative and Her-2 positive IDC-DCIS tumors (P=0.030, Mann-Whitney U test) and high negative correlation of miR-21 levels with PR levels (rho=-0.886, P=0.006, Spearman correlation). According to our results, IDC-DCIS breast carcinomas act in a different manner in pure IDC tumors with regard to the relations between miR-21 expression levels and the standard diagnostic and prognostic parameters, such as Her-2 status, ER and PR status and protein levels.",
journal = "Archives of Biological Sciences",
title = "Micro Rna-21 Expression Levels in Invasive Breast Carcinoma with a Non-Invasive Component",
volume = "67",
number = "4",
pages = "1285-1295",
doi = "10.2298/ABS150327105P"
}

Petrović, N., Jovanović-Ćupić, S. P., Brajušković, G., Lukić, S., Roganović, J., Krajnović, M. M.,& Mandušić, V.. (2015). Micro Rna-21 Expression Levels in Invasive Breast Carcinoma with a Non-Invasive Component. in Archives of Biological Sciences, 67(4), 1285-1295.
https://doi.org/10.2298/ABS150327105P

Petrović N, Jovanović-Ćupić SP, Brajušković G, Lukić S, Roganović J, Krajnović MM, Mandušić V. Micro Rna-21 Expression Levels in Invasive Breast Carcinoma with a Non-Invasive Component. in Archives of Biological Sciences. 2015;67(4):1285-1295.
doi:10.2298/ABS150327105P .

Petrović, Nina, Jovanović-Ćupić, Snežana P., Brajušković, Goran, Lukić, Silvana, Roganović, Jelena, Krajnović, Milena M., Mandušić, Vesna, "Micro Rna-21 Expression Levels in Invasive Breast Carcinoma with a Non-Invasive Component" in Archives of Biological Sciences, 67, no. 4 (2015):1285-1295,
https://doi.org/10.2298/ABS150327105P . .

TY  - JOUR
AU  - Stanojević, Boban
AU  - Saenko, Vladimir
AU  - Todorović, Lidija
AU  - Petrović, Nina
AU  - Nikolić, Dragan
AU  - Živaljević, Vladan R.
AU  - Paunović, Ivan R.
AU  - Nakashima, Masahiro
AU  - Yamashita, Shunichi
AU  - Džodić, Radan R.
PY  - 2014
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/340
AB  - Alterations of the von Hippel-Lindau (VHL) tumor suppressor gene can cause different hereditary tumors associated with VHL syndrome, but the potential role of the VHL gene in papillary thyroid carcinoma (PTC) has not been characterized. This study set out to investigate the relationship of VHL expression level with clinicopathological features of PTC in an ethnically and geographically homogenous group of 264 patients from Serbia, for the first time. Multivariate logistic regression analysis showed a strong correlation between low level of VHL expression and advanced clinical stage (OR=5.78, 95% CI 3.17-10.53, P LT 0.0001), classical papillary morphology of the tumor (OR=2.92, 95% CI 1.33-6.44, P=0.008) and multifocality (OR=1.96, 95% CI 1.06-3.62, P=0.031). In disease-free survival analysis, low VHL expression had marginal significance (P=0.0502 by the log-rank test) but did not appear to be an independent predictor of the risk for chance of faster recurrence in a proportion hazards model. No somatic mutations or evidence of VHL downregulation via promoter hypermethylation in PTC were found. The results indicate that the decrease of VHL expression associates with tumor progression but the mechanism of downregulation remains to be elucidated.
T2  - PLOS One
T1  - Low VHL mRNA Expression is Associated with More Aggressive Tumor Features of Papillary Thyroid Carcinoma
VL  - 9
IS  - 12
DO  - 10.1371/journal.pone.0114511
ER  - 

@article{
author = "Stanojević, Boban and Saenko, Vladimir and Todorović, Lidija and Petrović, Nina and Nikolić, Dragan and Živaljević, Vladan R. and Paunović, Ivan R. and Nakashima, Masahiro and Yamashita, Shunichi and Džodić, Radan R.",
year = "2014",
abstract = "Alterations of the von Hippel-Lindau (VHL) tumor suppressor gene can cause different hereditary tumors associated with VHL syndrome, but the potential role of the VHL gene in papillary thyroid carcinoma (PTC) has not been characterized. This study set out to investigate the relationship of VHL expression level with clinicopathological features of PTC in an ethnically and geographically homogenous group of 264 patients from Serbia, for the first time. Multivariate logistic regression analysis showed a strong correlation between low level of VHL expression and advanced clinical stage (OR=5.78, 95% CI 3.17-10.53, P LT 0.0001), classical papillary morphology of the tumor (OR=2.92, 95% CI 1.33-6.44, P=0.008) and multifocality (OR=1.96, 95% CI 1.06-3.62, P=0.031). In disease-free survival analysis, low VHL expression had marginal significance (P=0.0502 by the log-rank test) but did not appear to be an independent predictor of the risk for chance of faster recurrence in a proportion hazards model. No somatic mutations or evidence of VHL downregulation via promoter hypermethylation in PTC were found. The results indicate that the decrease of VHL expression associates with tumor progression but the mechanism of downregulation remains to be elucidated.",
journal = "PLOS One",
title = "Low VHL mRNA Expression is Associated with More Aggressive Tumor Features of Papillary Thyroid Carcinoma",
volume = "9",
number = "12",
doi = "10.1371/journal.pone.0114511"
}

Stanojević, B., Saenko, V., Todorović, L., Petrović, N., Nikolić, D., Živaljević, V. R., Paunović, I. R., Nakashima, M., Yamashita, S.,& Džodić, R. R.. (2014). Low VHL mRNA Expression is Associated with More Aggressive Tumor Features of Papillary Thyroid Carcinoma. in PLOS One, 9(12).
https://doi.org/10.1371/journal.pone.0114511

Stanojević B, Saenko V, Todorović L, Petrović N, Nikolić D, Živaljević VR, Paunović IR, Nakashima M, Yamashita S, Džodić RR. Low VHL mRNA Expression is Associated with More Aggressive Tumor Features of Papillary Thyroid Carcinoma. in PLOS One. 2014;9(12).
doi:10.1371/journal.pone.0114511 .

Stanojević, Boban, Saenko, Vladimir, Todorović, Lidija, Petrović, Nina, Nikolić, Dragan, Živaljević, Vladan R., Paunović, Ivan R., Nakashima, Masahiro, Yamashita, Shunichi, Džodić, Radan R., "Low VHL mRNA Expression is Associated with More Aggressive Tumor Features of Papillary Thyroid Carcinoma" in PLOS One, 9, no. 12 (2014),
https://doi.org/10.1371/journal.pone.0114511 . .

TY  - JOUR
AU  - Petrović, Nina
AU  - Mandušić, Vesna
AU  - Stanojević, Boban
AU  - Lukić, Silvana
AU  - Todorović, Lidija
AU  - Roganović, Jelena
AU  - Dimitrijević, Bogomir B.
PY  - 2014
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/6041
AB  - MicroRNA-21 (miR-21) overexpression is characteristic for various types of tumors, but it is still unknown whether its expression levels differ between invasive and non-invasive breast carcinomas. The main goal of the study was to determine the difference in miR-21 expression among normal tissue, non-invasive, invasive with non-invasive component, and pure invasive breast cancer samples, to explain its potential role and significance in breast cancer invasiveness. The second goal was to propose miR-21 as molecular marker of breast cancer invasiveness and potential target for future anti-miR therapies for the prevention of invasion and metastasis. In order to reveal the role of miR-21 in breast cancer invasiveness, we measured miR-21 expression levels in 44 breast cancer and four normal samples by stem-loop real-time RT-PCR using TaqMan technology. Relative expression levels of miR-21 were significantly higher in invasive than in other groups (P = 0.002) and significantly higher in invasive compared with invasive with non-invasive component group in histological (P = 0.043) and nuclear grade 2 (P = 0.036), estrogen-receptor-positive (ER+) (P = 0.006), progesterone-receptor-positive (PR+) (P = 0.008), ER+ PR+ (P = 0.007), and proliferation index (Ki-67) LT = 20 % (P = 0.036) tumors. Our findings suggest that miR-21 could be independent molecular marker of breast cancer invasiveness and potential target for future anti-miR therapies for the prevention of invasion and metastasis.
T2  - Medical Oncology
T1  - The difference in miR-21 expression levels between invasive and non-invasive breast cancers emphasizes its role in breast cancer invasion
VL  - 31
IS  - 3
DO  - 10.1007/s12032-014-0867-x
ER  - 

@article{
author = "Petrović, Nina and Mandušić, Vesna and Stanojević, Boban and Lukić, Silvana and Todorović, Lidija and Roganović, Jelena and Dimitrijević, Bogomir B.",
year = "2014",
abstract = "MicroRNA-21 (miR-21) overexpression is characteristic for various types of tumors, but it is still unknown whether its expression levels differ between invasive and non-invasive breast carcinomas. The main goal of the study was to determine the difference in miR-21 expression among normal tissue, non-invasive, invasive with non-invasive component, and pure invasive breast cancer samples, to explain its potential role and significance in breast cancer invasiveness. The second goal was to propose miR-21 as molecular marker of breast cancer invasiveness and potential target for future anti-miR therapies for the prevention of invasion and metastasis. In order to reveal the role of miR-21 in breast cancer invasiveness, we measured miR-21 expression levels in 44 breast cancer and four normal samples by stem-loop real-time RT-PCR using TaqMan technology. Relative expression levels of miR-21 were significantly higher in invasive than in other groups (P = 0.002) and significantly higher in invasive compared with invasive with non-invasive component group in histological (P = 0.043) and nuclear grade 2 (P = 0.036), estrogen-receptor-positive (ER+) (P = 0.006), progesterone-receptor-positive (PR+) (P = 0.008), ER+ PR+ (P = 0.007), and proliferation index (Ki-67) LT = 20 % (P = 0.036) tumors. Our findings suggest that miR-21 could be independent molecular marker of breast cancer invasiveness and potential target for future anti-miR therapies for the prevention of invasion and metastasis.",
journal = "Medical Oncology",
title = "The difference in miR-21 expression levels between invasive and non-invasive breast cancers emphasizes its role in breast cancer invasion",
volume = "31",
number = "3",
doi = "10.1007/s12032-014-0867-x"
}

Petrović, N., Mandušić, V., Stanojević, B., Lukić, S., Todorović, L., Roganović, J.,& Dimitrijević, B. B.. (2014). The difference in miR-21 expression levels between invasive and non-invasive breast cancers emphasizes its role in breast cancer invasion. in Medical Oncology, 31(3).
https://doi.org/10.1007/s12032-014-0867-x

Petrović N, Mandušić V, Stanojević B, Lukić S, Todorović L, Roganović J, Dimitrijević BB. The difference in miR-21 expression levels between invasive and non-invasive breast cancers emphasizes its role in breast cancer invasion. in Medical Oncology. 2014;31(3).
doi:10.1007/s12032-014-0867-x .

Petrović, Nina, Mandušić, Vesna, Stanojević, Boban, Lukić, Silvana, Todorović, Lidija, Roganović, Jelena, Dimitrijević, Bogomir B., "The difference in miR-21 expression levels between invasive and non-invasive breast cancers emphasizes its role in breast cancer invasion" in Medical Oncology, 31, no. 3 (2014),
https://doi.org/10.1007/s12032-014-0867-x . .